

Table of Contents

I	Executive Summary	4
II	Acute Coronary Syndromes	5
	• Antithrombotic Trials	5
	• Canadian ACS Registries	10
	• GRACE Registry	17
	• INTERACT	26
	• TRANSFER AMI Study	28
III	Cardio-Metabolic	30
	• ACTFAST Study	30
	• DRIVE Study	31
	• DYSIS	31
	• GOALL / VP	32
	• GUIDE / GUIDANC Registries ..	34
	• T2DM Registry	35
IV	ECG Core Laboratory	36
V	CAN-REDUCE / DM Scan	43
VI	Atrial Fibrillation	44
VII	Pulmonary Hypertension	45
VIII	Miscellaneous Studies	46

II ACUTE CORONARY SYNDROMES

Antithrombotic Trials

MANUSCRIPTS

1. Mahaffey KW, Tonev ST, Spinler SA, Levine GN, Gallo R, Ducas J, Goodman SG, Antman EM, Becker RC, Langer A, White HD, Aylward PE, Col JJ, Ferguson JJ, Califf RM; on behalf of the SYNERGY Trial Investigators. Obesity in patients with non-ST-segment elevation acute coronary syndromes: Results from the SYNERGY trial. *Int J Cardiol*. 2010;139:123-33.
2. Harrington RA, Stone G, McNulty S, White HD, Lincoff AM, Gibson CM, Pollack CV, Montalescot G, Mahaffey KW, Kleiman N, Goodman SG, Amine M, Angiolillo D, Becker R, Chew D, French W, Leisch F, Parikh K, Skerjanec S, Bhatt DL. Platelet Inhibition with Cangrelor in Patients Undergoing PCI. Results of the CHAMPION PCI Trial. *N Engl J Med* 2009; Epub ahead of print.
3. The APPRAISE Steering Committee and Investigators. Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor in Combination with Antiplatelet Therapy After Acute Coronary Syndrome: Results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) Trial. *Circulation* 2009;119:2877-85.
4. Bhatt DL, Lincoff AM, Gibson CM, Stone GW, McNulty S, Montalescot G, Kleiman NS, Goodman SG, White HD, Mahaffey KW, Pollack CV, Manoukian SV, Widimsky P, Chew DP, Cura F, Manukov I, Tousek F, Jafar MZ, Arneja J, Skerjanec S, Harrington RA, on behalf of the CHAMPION PLATFORM Investigators. Intravenous Platelet Blockade with Cangrelor During Percutaneous Coronary Intervention. *New Engl J Med* 2009; Epub ahead of print.
5. Yan RT, Yan AT, Mahaffey KW, White HD, Pieper K, Sun JL, Pepine CJ, Biasucci LM, Gulba DC, Lopez-Sendon J, Goodman SG. Prognostic Utility of Quantifying Evolutionary ST-Segment Depression on Early Follow-up Electrocardiogram in Patients with Non-ST-Segment Elevation Acute Coronary Syndromes. *Eur Heart J* Dec 23 2009; epub ahead of print.
6. Linefsky JP, Lin M, Pieper KS, Reist CJ, Berdan LG, Antman EM, Goodman SG, French JK, Guneri S, Roe MT, Newby LK, Harrington RA, Ferguson JJ, Califf RM, and Mahaffey KW. Comparison of Site-Reported and Core Laboratory-Reported Creatine Kinase-MB Values in Non-ST-Segment Elevation Acute Coronary Syndrome (from the International Trial SYNERGY). *Am J Cardiol* 2009;104:1330-1335.
7. Spinler SA, Gallup D, Levine GN, Ferguson JJ, Rao SV, Gallo R, Ducas J, Goodman SG, Antman E, White HD, Biasucci L, Becker RC, Col JJ, Cohen M, Harrington RA, Califf RM, Mahaffey KW. Relationship between renal function and outcomes in high-risk patients with non-ST-segment elevation acute coronary syndromes: results from SYNERGY. *Int J Cardiol*. 2009 Apr 28. [Epub ahead of print]
8. Mahaffey KW, Yang Q, Pieper KS, Antman EM, White HD, Goodman SG, Cohen M, Kleiman NS, Langer A, Aylward PE, Col JJ, Reist C, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Prediction of one-year survival in high-risk patients with acute coronary syndromes: results from the SYNERGY trial. *J Gen Intern Med* 2008;23:310-6.
9. Leung S, Gallup D, Mahaffey KW, Cohen M, Antman EM, Goodman SG, Harrington RA, Langer A, Aylward P, Ferguson JJ, Califf RM; SYNERGY Trial Investigators. Smoking status and antithrombin therapy in patients with non-ST-segment elevation acute coronary syndrome. *Am Heart J*. 2008;156:177-84.
10. Murphy SA, Antman E, Van de Werf F, Goodman SG, Mahaffey K, Menown I, Cohen M, Gibson CM. Efficacy and Safety of the Low-Molecular Weight Heparin Enoxaparin Compared with Unfractionated Heparin across the Acute Coronary Syndrome Spectrum: A Meta-Analysis. *Eur Heart J* 2007;28:2077-86.

Antithrombotic Trials

MANUSCRIPTS - CONTINUED

11. Jolly S, Tan M, Mendelsohn A, Fitchett D, Armstrong PW, Langer A, Goodman SG, Comparison of Effectiveness of Enoxaparin versus Unfractionated Heparin to Reduce Silent and Clinically Apparent Acute Myocardial Infarction in patients presenting with non-ST Segment Elevation Acute Coronary Syndrome. *Am J Cardiol* 2007;99:186-188.
12. Miller CD, Banerjee A, Mahaffey KW, Kontos M, Fermann G, Pollack CV, Antman EM, Aylward P, Goodman SG, Santos R, Ferguson JJ, Califf RM, Hoekstra JW. Treatment and Outcomes of Patients with Evolving Myocardial Infarction: Experiences from the SYNERGY Trial. *Eur Heart J* 2007;28:1079-84.
13. Murphy SA, Antman E, Van de Werf F, Goodman SG, Mahaffey K, Menown I, Cohen M, Gibson CM. Efficacy and Safety of the Low-Molecular Weight Heparin Enoxaparin Compared with Unfractionated Heparin across the Acute Coronary Syndrome Spectrum: A Meta-Analysis. *Eur Heart J* 2007;28:2077-86.
14. Cantor WJ, Mahaffey KW, Huang Z, Das P, Gulba DC, Glezer S, Gallo R, Ducas J, Cohen M, Antman EM, Langer A, Kleiman NS, White HD, Chisholm RJ, Harrington RA, Ferguson JJ, Califf RM, Goodman SG. Bleeding complications in patients with acute coronary syndrome undergoing early invasive management can be reduced with radial access, smaller sheath sizes, and timely sheath removal. *Catheter Cardiovasc Interv* 2007;69:73-83.
15. Tricoci P, Lokhnygina Y, Berdan LG, Steinhubl SR, Gulba DC, White HD, Kleiman NS, Aylward P, Langer A, Califf RM, Ferguson JJ, Antman EM, Newby LK, Harrington RA, Goodman SG, Mahaffey KW. Time to coronary angiography and outcomes among patients with high-risk non-ST segment elevation acute coronary syndromes: results from the Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) Trial. *Circulation* 2007;116:2669-77.
16. Goodman SG, Bozovich GE, Tan M, Dos Santos A, Gurfinkel EP, Cohen M, Langer A, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group (ESSENCE) Study Group. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST segment changes: The ESSENCE ECG Core Laboratory Substudy. *Am Heart J* 2006;151:791-797.
17. Cohen M, Mahaffey KW, Pieper K, Traylor L, Pollack CV Jr, Antman EM, Hoekstra J, Goodman SG, Langer A, Col JJ, White HD, Califf RM, Ferguson JJ; SYNERGY Trial Investigators. A subgroup analysis of the impact of prerandomization antithrombin therapy on outcomes in the SYNERGY trial: enoxaparin versus unfractionated heparin in non-ST-segment elevation acute coronary syndromes. *J Am Coll Cardiol* 2006;48:1346-54.
18. Mahaffey KW, Cohen M, Garg J, Antman E, Kleiman NS, Goodman SG, Berdan LG, Reist CJ, Langer A, White HD, Aylward P, Col JJ, Ferguson JJ, Califf RM, on behalf of the SYNERGY Trial Investigators. High-Risk Patients with Acute Coronary Syndromes treated with Low Molecular Weight or Unfractionated Heparin: Outcomes at 6 months and 1 year in the SYNERGY Trial. *JAMA* 2005;294:2594-2600.
19. The SYNERGY Trial Investigators. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST segment elevation acute coronary syndromes managed with an intended early invasive strategy. Primary results of the SYNERGY randomized trial. *JAMA* 2004;292:45-54.
20. Petersen JL, Mahaffey KW, Becker RC, Goodman SG, Kleiman NS, Marian AJ, Stone GW, Lansky AJ, Lincoff AM, Hazen SL, Nessel CC, Toro-Figueroa L, Tate L, Reist CJ, Cohen M, Califf RM, Ferguson JJ. Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: Design and rationale of the SYNERGY Library. *Am Heart J* 2004;148:269-276.

21. Petersen JL, Mahaffey KW, Hasselblad V, Antman E, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, DeLemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E; Califf RM. Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview. *JAMA* 2004;292:89-96.
22. Spinler SA, Inverso SM, Cohen M, Goodman SG, Stringer KA, Antman EM, for the ESSENCE and TIMI 11B investigators. Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies. *Am Heart J* 2003;146:33-41.
23. Antman EM, Cohen M, McCabe C, Goodman SG, Murphy SA, Braunwald E. Enoxaparin is superior to unfractionated heparin for preventing clinical events at one year follow-up of TIMI 11B and ESSENCE. *Eur Heart J* 2002;23:308-14.
24. Goodman SG, Barr A, Sobtchouk A, Cohen M, Fromell GJ, Laperrière L, Hill C, Langer A, for the Canadian Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) ST Segment Monitoring Substudy Group. Low molecular weight heparin decreases rebound ischemia in unstable angina or non-Q wave myocardial infarction: The Canadian ESSENCE ST segment monitoring substudy. *J Am Coll Cardiol* 2000;36:1507-1513.
25. Goodman SG, Cohen M, Bigonzi F, Gurfinkel EP, Radley DR, Le Louer V, Fromell GJ, Demers C, Turpie AGG, Califf RM, Fox KAA, Langer A, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: one year results of the ESSENCE study. *J Am Coll Cardiol*, 2000;36:693-98.
26. Cohen M, Stinnett S, Weatherly B, Gurfinkel EP, Fromell GJ, Goodman SG, Califf RM, Fox KAA, Lee KL, for the ESSENCE Study Group. Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy. *Am Heart J* 2000;139:962-70.
27. O'Brien BJ, Willan A, Blackhouse G, Goeree R, Cohen M, Goodman S. Is the use of low- molecular-weight heparin (enoxaparin) in acute coronary syndrome patients cost saving in Canada? *Am Heart J* 2000;139:423-29.
28. Fox KAA, Goodman S, Bigonzi F, Le Louer V, Cohen M, and the ESSENCE Trial Investigators. Inter-regional differences and outcome in unstable angina: analysis of the international ESSENCE trial. *Eur Heart J* 2000;21:1433-39.
29. Cohen M, Demers C, Gurfinkel EP, Turpie AGG, Fromell GJ, Goodman S, Langer A, Califf RM, Fox KAA, Premeureur J, Bigonzi F, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. *N Eng J Med* 1997;337:447-452.

Antithrombotic Trials

ABSTRACTS

1. Yan RT, Yan AT, Mahaffey KW, White HD, Pepine CJ, Biasucci LM, Gulba DC, Lopez-Sendon J, Goodman SG, on behalf of the SYNERGY Investigators. Prognostic Significance Of Evolving St-Segment Depression On Admission And Early Repeat Electrocardiograms In Non-St Elevation Acute Coronary Syndromes: Insights From The Synergy Trial. *Can J Cardiol* 2008;24(Suppl E):259E.
2. Yan RT, Yan AT, Mahaffey KW, White HD, Pieper K, Sun JL, Pepine CJ, Biasucci LM, Gulba DC, Lopez-Sendon J, Goodman SG, on behalf of the SYNERGY Investigators. Prognostic Significance Of Evolving St-Segment Depression On Admission And Early Repeat Electrocardiograms In Non-St Elevation Acute Coronary Syndromes: Insights From The Synergy Trial. *Circulation* 2008;118(Suppl 2):S578.
3. Goodman SG, Mahaffey KW, Chiswell K, Cohen M, Kontos MC, Antman EM, Ferguson JJ, Califf RM, Becker R. Activated partial thromboplastin time measurement is not associated with clinical outcomes in patients with high-risk non-ST segment elevation acute coronary syndromes treated with unfractionated heparin. *J Am Coll Cardiol* 2007;49(Suppl A):186A.
4. Tricoci P, Mahaffey KW, O'Grady KG, Pieper KS, Newby LK, Harrington RA, Goodman SG, Gulba DC, Col J, White HD, Aylward PE, French JK, Kleiman NS, Ferguson JJ, Califf RM. Troponin elevation after percutaneous coronary intervention predicts major cardiac adverse outcomes in patients with non ST segment elevation acute coronary syndromes: results from the SYNERGY trial. *J Am Coll Cardiol* 2007;49(Suppl B):22B.
5. Linefsky JP, Mahaffey KW, Pieper KS, Lin A, Reist CJ, Antman E, Goodman SG, French JK, Roe MT, Harrington RA, Ferguson JJ, Califf RM. Differences between site-reported and core laboratory creatine kinase-MB values in an international clinical trial: results from the SYNERGY trial. *Circulation* 2006;114(suppl):II-417.
6. Shishehbor M, Lincoff AM, Lansky A, Mahaffey KW, Stone G, Yang H, Marian AJ, Ferguson JJ, Califf RM, Goodman SG, Kleiman NS, Topol E, Hazen SL, Becker RC. Lipid peroxidation products independently predict mortality in patients presenting with non-ST segment elevation acute coronary syndromes: a SYNERGY Library analysis. *Circulation* 2005; 112(Suppl):II-388.
7. Shishehbor M, Lincoff AM, Yang H, Mahaffey KW, Becker RC, Goodman SG, Lansky A, Marian AJ, Stone G, Kleiman NS, Ferguson JJ, Califf RM, Topol E, Hazen SL. Plasminogen activator inhibitor-1 activity predicts clinical outcome in patients presenting with non-ST-segment elevation acute coronary syndromes: a SYNERGY Library analysis. *Circulation* 2005; 112(Suppl):II-140.
8. Petersen JL, Reist CJ, Col JJ, Anderson FA, Fox KAA, Goodman SG, Langer A, Ferguson JJ. Patient characteristics and clinical events from GRACE and SYNERGY: differences persist in utilization of standard therapies in clinical practice. *Circulation* 2005; 112(Suppl):II-776
9. Rao SV, Mahaffey KW, Antman E, Kleiman NS, Ferguson JJ, Califf RM, Becker RC, Goodman SG, Aylward PE. Predictors of Major Bleeding and Transfusion in SYNERGY: Effects of Pretreatment Variables and Treatment Assignment. *JACC* 2005;45(Suppl A):247A.
10. Ferguson JJ, Mahaffey KW, Huang Y, Armstrong PW, Levine G, Kleiman NS, Goodman SG, Cohen M, Antman E, Califf RM. Enoxaparin Versus Unfractionated Heparin: Consequences of Treatment Duration on Efficacy and Safety in SYNERGY. *JACC* 2005;45(Suppl A):247A.
11. Mahaffey KW, Levine G, Gallo R, Ducas J, Goodman SG, Lokhnygina Y, Traylor L, Antman E, White HD, Becker RC, Col JJ, Cohen M, Harrington RA, Ferguson JJ, Califf RM. Relationships Between Renal Function, Age, and Obesity and Outcomes in High-Risk Patients with Acute Coronary Syndromes: Results from SYNERGY. *JACC* 2005;45(Suppl A):214A.
12. Cohen M, Mahaffey KW, Berdan LG, Reist CJ, Traylor L, Langer A, Goodman SG, Antman E, Dietrich F, Califf RM, Ferguson JJ. Superiority of Enoxaparin Low-Molecular-Weight Heparin Over Unfractionated Heparin in Patients With No Prior Antithrombin Therapy or Maintained on Consistent Antithrombin Therapy: Results From SYNERGY. *JACC* 2005;45(Suppl A):202A.

13. Cantor WJ, Goodman SG, Gallup D, Mahaffey KW, Gulba DC, Cohen M, Antman EM, Langer A, Kleiman NS, White HD, Chisholm RJ, Harrington RA, Ferguson JJ, Califf RM. Major Access Site Bleeding in Acute Coronary Syndrome Patients Undergoing Early Invasive Management can be Reduced With Radial Access and Smaller Sheath Sizes. Observations from the SYNERGY Trial. *JACC* 2005;45(Suppl A):191A.
14. Goodman SG, Bozovich G, Tan M, Dos Santos A, Hassan Q, Naebkhil A, Cohen M, Langer A, Bigonzi F, The ESSENCE Study Group. The greatest benefit of enoxaparin (low molecular weight heparin) over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST segment depression. *Circulation* 2001;104(suppl.II):II-549.
15. Batchelor WB, Radley D, Cohen M, Turpie AGG, Langer A, Goodman S. A comparison of the impact of practice patterns on the outcomes of patients with acute coronary syndromes in the USA and Canada: post hoc analysis of ESSENCE and TIMI 11B. *J Am Coll Cardiol* 2001;37(suppl A):359A.
16. Goodman S, Langer A, Demers C, Turpie A, Bigonzi F, Radley D, Le louer V, Gosset F, Fromell G, Cohen M, for the ESSENCE Group. One year follow-up of the ESSENCE Trial (Enoxaparin vs. heparin in unstable angina/non Q wave myocardial infarction):sustained clinical benefit. *Can J Cardiol* 1998;14(suppl. F):122F.
17. Goodman S, Omarali I, Sobtchouk A, Barr A, Langer A, Cohen M, for the Canadian ESSENCE Holter Substudy Group. Low molecular weight heparin decreases rebound ischemia in unstable angina/non Q wave MI: the Canadian ESSENCE Holter substudy. *Can J Cardiol* 1998;14(suppl. F):122F.
18. Goodman S, Bigonzi F, Radley D, Le louer V, Gosset F, Cohen M, for the ESSENCE Group. One year follow-up of the ESSENCE Trial (Enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction). *Eur Heart J* 1998;19:50.
19. Cohen M, Bigonzi F, Le louer V, Gosset F, Fromell GJ, Goodman S, for the ESSENCE Group. One year follow-up of the ESSENCE Trial (Enoxaparin versus heparin in unstable angina and non-Q-wave myocardial infarction). *J Am Coll Cardiol* 1998;31(suppl. A):79A.
20. Cohen M, Turpie AGG, Demers C, Gurfinkel E, Fromell G, Langer A, Goodman S, Califf R, Fox K, Premmereur J, Bigonzi F, for the ESSENCE Group. Blind comparison of enoxaparin (a low molecular weight heparin) with standard heparin in the treatment of unstable coronary artery disease “the ESSENCE trial”. *Thromb Haemost* 1997;77(suppl.):374.
21. Cohen M, Weatherley B, Lee KL, Gurfinkel EP, Fromell G, Goodman S, Fox KAA. Multivariable analysis of predictors of recurrent ischemic events and death in unstable angina and non-Q wave infarction after treatment with combination antithrombotic therapy: results from the ESSENCE trial. *Circulation* 1997;96(suppl.):I-596.
22. Omarali I, Sobtchouk A, Barr A, Goodman S, Cohen M, Langer A. Low molecular weight heparin decreases ischemia and ischemic rebound in acute coronary syndromes: ESSENCE substudy. *Circulation* 1997;96(suppl.):I-597.

Canadian ACS Registries

MANUSCRIPTS

1. Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Manfrini O, Goodman SG, on behalf of the Canadian Acute Coronary Syndrome Registry I and II Investigators. Factors influencing underutilization of evidence-based therapies in women. *Eur Heart J* 2011;32:1337-44.
2. Hutchinson-Jaffe AB, Goodman SG, Yan RT, Elbarouni B, Rose B, Eagle KA, Lai CC, Baer C, Langer A, Yan AT, on behalf of the Canadian Acute Coronary Syndromes (ACS) Registry I and II Investigators, and the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Comparison of Baseline Characteristics, Management and Outcome in Patients with Non-ST-segment Elevation Acute Coronary Syndrome In Versus Not In Clinical Trials. *Am J Cardiol* 2010;106:1389-1396.
3. Bagnall AJ, Yan AT, Yan RT, Lee CH, Tan M, Baer C, Polasek P, Fitchett DH, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes (ACS) Registry II Investigators. Optimal Medical Therapy For Non-ST-Elevation Acute Coronary Syndromes: Exploring Why Physicians Do Not Prescribe Evidence-Based Treatment and Why Patients Discontinue Medications After Discharge. *Circ Cardiovasc Qual Outcomes* 2010;3:530-537.
4. Elbarouni B, Elmanfud O, Yan RT, Fox KAA, Kornder JM, Rose R, Spencer FA, Welsh RC, Wong GC, Goodman SG, Yan AT. Temporal Trend of In-hospital Major Bleeding Among Patients with Non ST-elevation Acute Coronary Syndromes. *Am Heart J* 2010;160:420-7.
5. Baslaib F, Alkaabi S, Yan AT, Yan RT, Dorian P, Nanthakumar K, Casanova A, Goodman SG. QRS Prolongation in Patients with Acute Coronary Syndromes. *Am Heart J* 2010;159:593-8.
6. Lee TC, Goodman SG, Yan RT, Grondin FR, Welsh RC, Rose B, Gyenes B, Zimmerman RH, Brossoit R, Saposnik G, Yan AT. Disparities in Management Patterns and Outcomes of Non-ST Elevation Acute Coronary Syndrome Patients With and Without Prior History of Cerebrovascular Disease. *Am J Cardiol* 2010;105:1083-1089.
7. Wong JA, Goodman SG, Yan RT, Wald R, Bagnall AJ, Welsh RC, Wong GC, Kornder J, Eagle KA, Steg PG, Yan AT, on behalf of the Canadian Acute Coronary Syndromes I and II, and Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Principal Author. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. *Eur Heart J* 2009;30:549-57.
8. Yan AT, Yan RT, Huynh T, Casanova A, Raimondo FE, Fitchett DH, Langer A, Goodman SG. Understanding Physicians' Risk Stratification of Acute Coronary Syndromes: Insights from the Canadian ACS II Registry. *Arch Int Med* 2009;169(4): 372-378.
9. Segev A, Fefer P, Strauss BH, Matetzky S, Tan M, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registries Investigators. Outcome of patients with acute coronary syndromes enrolled in clinical trials. *Coronary Artery Disease* 2009 (in press).
10. Alkaabi S, Baslaib F, Casanova A, Yan AT, Fitchett D, Mendelsohn A, Nikhil JY, Langer A, Goodman SG, on behalf of the Canadian Acute Coronary Syndrome Registry Investigators. Clinical implications of a next-day follow-up electrocardiogram in patients with non-ST elevation acute coronary syndromes. *Am Heart J* 2008;156:797-803.
11. Elbarouni B, Goodman SG, Yan RT, Casanova A, Al-Hesayen A, Pearce S, Fitchett DF, Langer A, Yan AT, for the Canadian ACS Registries Investigators. Impact of Delayed Presentation on Management and Outcome of Non-ST Elevation Acute Coronary Syndromes. *Am Heart J* 2008;156(2):262-268
12. Lim KD, Yan AT, Casanova A, Yan RT, Mendelsohn A, Jolly S, Fitchett DH, Langer A, Goodman SG. Quantitative troponin elevation does not provide incremental prognostic value beyond comprehensive risk stratification in patients with Non-ST segment elevation acute coronary syndromes. *Am Heart J*. 2008 Apr;155(4):718-24

13. Vijayaraghavan R, Yan AT, Tan M, Fitchett DH, Georgescu AA, Hassan Q, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes Registry Investigators. Local Hospital vs. Core-Laboratory Interpretation of the Admission Electrocardiogram in Acute Coronary Syndromes: Increased Mortality in Patients with Unrecognized ST-Elevation Myocardial Infarction. *Eur Heart J*. 2008 Jan;29(1):31-7.
14. Lee CH, Tan M, Yan AT, Yan RT, Fitchett D, Grima EA, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes II (ACS II) Registry Investigators. The Utilization of Cardiac Catheterization for Non-ST-Segment Elevation Acute Coronary Syndromes According to Initial Risk: Reasons Why Physicians Choose Not to Refer Their Patients. *Arch Intern Med* 2008;168(3):291-296.
15. Segev A, Strauss BH, Tan M, Buller CE, Mendelsohn AA, Langer A, Goodman SG. Risk factors and outcome of in-hospital ischemic stroke in patients with non-ST elevation acute coronary syndromes. *Int J Cardiol* 2007 Oct 30. [Epub]; *Int J Cardiol* 2008;129:233–237.
16. Yan AT, Yan RT, Tan M, Huynh T, Soghrati K, Brunner LJ, DeYoung P, Fitchett DH, Langer A, Goodman SG, for the Canadian ACS Registries Investigators. Optimal Medical Therapy at Discharge in Patients with Acute Coronary Syndromes: Temporal Changes, Characteristics, and 1-year Outcome. *Am Heart J* 2007;154:1108-15.
17. Zia MI, Goodman SG, Peterson ED, Mulgund J, Chen AY, Langer A, Tan M, Ohman EM, Gibler WB, Pollack Jr CV, Roe MT. Paradoxical Utilization of Invasive Cardiac Procedures for Patients with Non ST-segment Elevation Myocardial Infarction: An International Perspective from the CRUSADE Initiative and Canadian ACS Registries. *Can J Cardiol* 2007;23:1073-79.
18. Yan A, Yan R, Tan M, Fung A, Cohen E, Fitchett D, Langer A, Goodman SG. Management Patterns in Relation to Risk Stratification Among Patients with non-ST Elevation Acute Coronary Syndromes. *Arch Int Med* 2007;167:1009-16.
19. Yan AT, Yan RT, Tan M, Casanova A, Labinaz M, Sridhar K, Fitchett DH, Langer A, Goodman SG. Risk Scores for Risk Stratification in Acute Coronary Syndromes: Useful But Simpler is Not Necessarily Better. *Eur Heart J* 2007;28(9):1072-78.
20. Yan RT, Yan AT, Tan M, McGuire DK, Leiter LA, Fitchett DH, Lauzon C, Lai K, Chow CM, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Under-utilization of evidence-based treatment partly explains the worse clinical outcome in diabetic patients with acute coronary syndromes. *Am Heart J* 2006;152:676-83.
21. Yan AT, Yan RT, Tan M, Chow CM, Fitchett DH, Georgescu A, Hassan Q, Luchansky J, Langer A, Goodman SG. ST-segment depression in non-ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. *Am Heart J* 2006;152(2):270-76.
22. Segev A, Strauss BH, Tan M, Mendelsohn AA, Lai K, Ashton T, Fitchett D, Grima E, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registries Investigators. Prognostic significance of admission heart failure in patients with non ST-elevation acute coronary syndromes (From the Canadian Acute Coronary Syndrome Registries). *Am J Cardiol* 2006;98:470-473.
23. Yan AT, Yan RT, Tan M, Constance C, Lauzon C, Zaltzman J, Wald R, Fitchett D, Langer A, Goodman SG. Treatment and outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes. *Can J Cardiol* 2006;22(2):115-120.
24. Yan R, Yan AT, Tan M, Chow CM, Fitchett DH, Ervin FL, Cha JYM, Langer A, Goodman SG. Age related differences in the management and outcome of patients with acute coronary syndromes: Insights from the Canadian Acute Coronary Syndrome Registry. *Am Heart J* 2006;151:352-59.

Canadian ACS Registries

MANUSCRIPTS - CONTINUED

25. Yan AT, Yan RT, Mary Tan M, Eagle KA, Granger CB, Dabbous OH, Fitchett D, Grima E, Langer A, and Goodman SG, for the Canadian Acute Coronary Syndromes (ACS) Registry Investigators. In-Hospital Revascularization and One-Year Outcome of Acute Coronary Syndrome Patients Stratified by the GRACE Risk Score. *Am J Cardiol* 2005;96:913–916.
26. Jackevicius CA, Alter D, Cox J, Daly P, Goodman S, Filate W, Newman A, Tu JV, for the Canadian Cardiovascular Outcomes Research Team. Acute treatment of myocardial infarction in Canada 1999-2002. *Can J Cardiol* 2005;21:145-152.
27. Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes Registries Investigators. Predictors and One-Year Outcome of Major Bleeding in Patients with Non-ST Elevation Acute Coronary Syndromes: Insights from the Canadian Acute Coronary Syndrome Registries. *Am Heart J* 2005;150(4):690-94.
28. Yan AT, Jong P, Yan RT, Tan M, Fitchett D, Chow CM, Roe MT, Pieper KS, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes (ACS) Registry Investigators. Clinical trial–derived risk model may not generalize to real-world patients with acute coronary syndrome. *Am Heart J* 2004;148:1020-27.
29. Yan AT, Yan RT, Tan M, Chow CM, Fitchett D, Stanton E, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes (ACS) Registry Investigators. Troponin is more useful than creatine kinase in predicting one-year mortality among acute coronary syndrome patients. *Eur Heart J* 2004;25:2006-2012.
30. Yan AT, Tan M, Fitchett D, Chow CM, Fowles RA, McAvinue TG, Roe MT, Peterson ED, Tu JV, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes Registry Investigators. One-Year Outcome of Patients After Acute Coronary Syndromes (from the Canadian Acute Coronary Syndromes Registry). *Am J Cardiol* 2004;94:25–29.

Canadian ACS Registries

ABSTRACTS

1. Elbarasi E, Goodman SG, Yan RT, Casanova A, Tan M, Hackam DG, Leiter LA, Langer A, Yan AT. Management of risk factors among ambulatory patients at high cardiovascular risk in Canada: Can we do better? *Can J Cardiol* 2010;26(Suppl D):89D.
2. Elbarouni B, Hutchinson-Jaffe AB, Goodman SG, Yan RT, Baer C, Lai C, Eagle KA, Langer A, Rose BF, Wald R, Yan AT. Differences in the baseline characteristics and management of non-ST segment elevation myocardial infarction patients as a function of participation in clinical trials. *Can J Cardiol* 2010;26(Suppl D):55D.
3. Bugiardini R, Yan AT, Yan RT, Fitchett D, Langer A, Goodman SG, Manfrini O, on behalf of the Canadian Acute Coronary Syndrome Registry and II Investigators. Underutilization influencing factors of evidence based therapies in women. *J Am Coll Cardiol* 2010;55(suppl A):A120.
4. Yan AT, Elmanfud O, Yan RT, Elbarouni B, Wong GC, Kornder JM, Rose BF, Welsh RC, Goodman SG. Temporal trend of in-hospital major bleeding in Canadian patients with non-ST elevation acute coronary syndromes. *Can J Cardiol* 2009; 25(Suppl B):140B.
5. Ismaeil NH, Goodman SG, Yan RT, DeYoung JP, Gallo R, Caer C, Ramanathan K, Yan AT. Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for acute coronary syndrome (ACS). *Can J Cardiol* 2009; 25(Suppl B):133B.
6. Lee TC, Goodman SG, Yan RT, Grondin FR, Welsh RC, Rose B, Gyenes, Zimmerman RH, Brossoit R, Saposnik G, Yan AT. Disparities in management patterns and outcomes of non-ST elevation acute coronary syndrome patients with and without prior history of cerebrovascular disease. *Can J Cardiol* 2009; 25(Suppl B):116B.

7. Yan AT, Yan RT, Huynh T, Casanova A, Raimondo FE, Fitchett DH, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry II Investigators. Understanding Physicians' Risk Stratification of Acute Coronary Syndromes: Insights from the Canadian ACS II Registry. *Circulation* 2008;118(Suppl 2):S968.
8. Wong JA, Goodman SG, Yan RT, Wald R, Gore J, Wong GC, Gallo R, Welsh RC, Grondin FR, Kornder JM, De Young P, Bagnall AJ, Rose B, Fox KAA, Yan AT, on behalf of ACS Registries & GRACE Investigators. Temporal Patterns in the Management of Non-ST Elevation Acute Coronary Syndromes in Patients With Renal Dysfunction and Associated Outcomes. *Can J Cardiol* 2008;24(Suppl E):259E.
9. Elbarouni B, Goodman SG, Yan RT, Casanova A, Al-Hesayen A, Pearce S, Fitchett DH, Langer A, Yan AT, on behalf of the ACS II Registry Investigators. Impact Of Delayed Presentation On Management And Outcome Of Non-St Elevation Acute Coronary Syndromes. *Can J Cardiol* 2008;24(Suppl E):262E.
10. Bagnall AJ, Goodman SG, Lee CH, Huynh T, Fam NP, Fitchett D, Langer A, Cheema AN, Yan RT, Yan AT, for the Canadian ACS Registry I & II Investigators. Evidence-Based Medical Therapy At 1-Year Following Acute Coronary Syndromes: Influence Of Initial Management Strategy And Revascularization. *Can J Cardiol* 2008;24(Suppl E):327E.
11. Bagnall AJ, Goodman SG, Huynh T, Cheema AN, Fitchett DH, Yan RT, Langer A, Yan AT, for the Canadian ACS Registry I and II Investigators. Temporal Changes in the Use of Early Invasive Management for Non-ST Elevation Acute Coronary Syndromes: Influence of Age on Treatment Selection and Outcome. *J Am Coll Cardiol* 2008;51(Suppl A):A216.
12. Huynh T, Yan A, Kouz S, Rinfret S, Schampaert E, Eisenberg MJ, Lauzon C, Afilalo M, Goodman S. A new risk score (C-AMI) for the early stratification of patients with ST-segment Elevation Myocardial Infarction. *Circulation* 2007;116(Suppl 2):II-317.
13. Yan AT, Yan RG, Tan M, Sridhar K, Labinaz M, Cohen EA, Fitchett DH, Langer A, Goodman SG. Comparison of the TIMI and GRACE Risk scores in the Canadian Acute Coronary Syndromes II Registry: simpler is not necessarily better. *J Am Coll Cardiol* 2006;47(Suppl A):224A.
14. Yan RT, Yan AT, Allegrone J, Lopez-Sendon J, Granger C, Gore J, Budaj A, Georgescu A, Hassan Q, Goodman SG. Failure To Identify St-Segment Deviation Or Left Bundle Branch Block On The Presenting Electrocardiograms In Patients With Acute Coronary Syndromes Is Related To More Adverse Clinical Outcome. *Can J Cardiol* 2006; 22(Suppl D):194D.
15. Yan RT, Yan AT, Allegrone J, Kennelly B, Budaj A, Georgescu A, Hassan Q, Goodman SG. ST-segment Depression in Non-ST Elevation Acute Coronary Syndromes: Quantitative Analysis Does Not Provide Incremental Prognostic Value Beyond Comprehensive Risk Stratification. *Can J Cardiol* 2006; 22(Suppl D):190D.
16. Lee C, Yan AT, Yan RT, Tan M, Grima E, De Young JP, Fitchett D, Langer A, Goodman SG. The Use of Anti-platelets and Anti-thrombotics in Non-ST Elevation Acute Coronary Syndromes – The Reasons Physicians choose Not to Prescribe. *Can J Cardiol* 2006; 22(Suppl D):192D.
17. Yan AT, Yan RT, Tan M, Lee C, Fitchett D, Langer A, Goodman SG. The Association Between On-Site Availability and Use of Cardiac Catheterization Facilities in the Contemporary Management of Non-ST Elevation Acute Coronary Syndromes. *Can J Cardiol* 2006; 22(Suppl D):194D.
18. Yan RT, Yan AT, Tan M, Baer C, Leiter LA, Chow CM, Fitchett DH, Langer A, Goodman SG. Underutilization of an Invasive Management Strategy in Canadian Diabetic Patients with Non-ST Elevation Acute Coronary Syndromes: The Problem Still Remains. *Circulation* 2005;112(Suppl):II-694.

Canadian ACS Registries

ABSTRACTS - CONTINUED

19. Yan AT, Yan RT, Tan M, Sridhar K, Labinaz M, Cohen EA, Fitchett DH, Langer A, Goodman SG. Comparison of the TIMI and GRACE Risk Scores in the Canadian Acute Coronary Syndromes II Registry: Simpler isn't Necessarily Better. *Can J Cardiol* 2005;21(Suppl C):218C.
20. Yan RT, Yan AT, Tan M, Baer C, Leiter LA, Chow CM, Fitchett DH, Langer A, Goodman SG. Underutilization of an Invasive Management Strategy in Canadian Diabetic Patients with Non-ST Elevation Acute Coronary Syndromes: The Problem Still Remains. *Can J Cardiol* 2005;21(Suppl C):164C.
21. Yan AT, Yan RT, Tan M, Ma PT, Lim KD, Chow CM, Fitchett DH, Langer A, Goodman SG. Greater Use of Evidence-Based Medical Therapies in Non-ST Elevation Acute Coronary Syndromes Over Time: Insights from the Canadian ACS Registries. *Can J Cardiol* 2005;21(Suppl C):162C.
22. Yan AT, Yan RT, Tan M, Fung AY, Chow CM, Cantor WJ, Cohen EA, Fitchett DH, Langer A, Goodman SG, for the Canadian ACS Registry Investigators. Despite the Temporal Increases, Coronary Angiography and Revascularization Remains Paradoxically Directed Towards Low Risk Non-ST Elevation Acute Coronary Syndrome Patients in Canada. *JACC* 2005;45(Suppl A):190A.
23. Yan RT, Yan AT, Tan M, Oh M, Zaltzman JS, Wald R, Fitchett DH, Langer A, Goodman SG. Evidence-based therapies for acute coronary syndromes are equally effective but underutilized among patients with renal dysfunction. *Circulation* 2004;110(Suppl III):III-576.
24. Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG. Predictors and long-term outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. *Circulation* 2004;110(Suppl III):III-574.
25. Chow CM, Tan M, Fitchett DH, Langer A, Goodman SG, Rudski L, for the Canadian ACS Registry Investigators. Outcomes of Early vs. Late Coronary Artery Bypass Graft post-acute myocardial infarction: Insights from the Canadian Acute Coronary Syndrome Registry. *Can J Cardiol* 2004;20(Suppl D):170D.
26. Yan AT, Yan RT, Tan M, Fung AY, Chow CM, Cantor WJ, Cohen EA, Fitchett DH, Langer A, Goodman SG, for the Canadian ACS Registry Investigators. Despite the Temporal Increases, Coronary Angiography and Revascularization Remains Paradoxically Directed Towards Low Risk Non-ST Elevation Acute Coronary Syndrome Patients in Canada. *Can J Cardiol* 2004;20(Suppl D):131D.
27. Yan AT, Yan RT, Tan M, Georgescu AA, Hassan Q, Luchansky J, Chow CM, Fitchett DH, Langer A, Goodman SG, for the Canadian ACS Registry Investigators. ST Segment Depression is an Independent Predictor of One-year Mortality in Non-ST Elevation Acute Coronary Syndromes But Quantitative ST-segment Analysis Does Not Provide Incremental Predictive Value Beyond Comprehensive Risk Stratification. *Can J Cardiol* 2004;20(Suppl D):124D.
28. Yan RT, Yan AT, Tan M, Oh M, Zaltzman J, Wald R, Fitchett DH, Langer A, Goodman SG, for the Canadian ACS Registry Investigators. Evidence-based Therapies For Acute Coronary Syndromes Are Equally Effective But Underutilized Among Patients with Renal Dysfunction. *Can J Cardiol* 2004;20(Suppl D):122D.
29. Yan AT, Jong P, Yan R, Tan M, Kuritzky RA, Drozdiak L, Chow CM, Fitchett DH, Langer A, Goodman SG. Risk scores derived from clinical trials do not generalize to real world acute coronary syndrome patients: insights from the Canadian Acute Coronary Syndromes Registry. *J Am Coll Cardiol* 2004;43(5;Suppl A):262A.
30. Yan R, Yan AT, Tan M, Leiter L, Chow CM, Fitchett DH, Fowles R, Janzen I, Langer A, Goodman SG. Diabetic patients with acute coronary syndromes were undertreated and had worse one-year outcome. *J Am Coll Cardiol* 2004;43(5;Suppl A):248A.
31. Yan R, Yan AT, Tan M, Chow CM, Fitchett DH, Ervin FL, Martin H, Cha JY, Langer A, Goodman SG. Elderly acute coronary syndrome patients were undertreated with worse one-year outcome: findings from a contemporary registry. *J Am Coll Cardiol* 2004;43(5;Suppl A):183A.

32. Zia M, Goodman SG, Row MT, Mulgand J, Langer A, Tan M, Ohman EM, Gibler WB, Pollack CV, Peterson ED. Paradoxical utilization of invasive cardiac procedures for patients with non-ST segment elevation myocardial infarction: an American-Canadian comparison from the CRUSADE initiative and Canadian registries. *J Am Coll Cardiol* 2004;43(5;Suppl A):276A.
33. Yan R, Yan AT, Tan M, Chow CM, Fitchett DH, Zaltzman JS, Pearce S, Langer A, Goodman SG. Renal dysfunction in patients with acute coronary syndromes is associated with worse mortality and myocardial infarction at one year follow-up. *Circulation* 2003;108(suppl):IV-314.
34. Yan AT, Yan R, Tan M, Stanton E, Lawrence M, Chow CM, Fitchett DH, Langer A, Goodman SG. Troponin status is more useful than creatine kinase in predicting one-year mortality in acute coronary syndrome patients. *Circulation* 2003;108(suppl):IV-313.
35. Chow CM, Yan AT, Yan R, Tan M, Adams GS, Lahey K, Fitchett DH, Langer A, Goodman SG. Admission and follow-up ECG classifications of acute coronary syndromes: a tale of tow systems (ST versus Q wave status). *Circulation* 2003;108(suppl):IV-383-384.
36. Vijayaraghavan R, Tan M, Fitchett DH, Georgescu AA, Hassan Q, Luchansky J, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Canadian Hospital vs. Core-Laboratory Interpretation of the Admission ECG in Acute Coronary Syndromes: The Impact of Disagreement on Treatments and Outcomes. *Can J Cardiol* 2003;19(suppl A):124A.
37. Chow CM, Tan M, Abramson BL, De Young JP, Watt M, Burrows M, Fitchett DH, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Gender Differences in Acute Myocardial Infarction (MI): Contemporary Canadian Practice and Outcomes. *Can J Cardiol* 2003;19(suppl A):257A.
38. Yan AT, Yan R, Tan M, Stanton E, Lawrence M, Chow CM, Fitchett DH, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Troponin Status Is More Useful Than Creatinine Kinase In Predicting One-year Mortality in Canadian Acute Coronary Syndrome Patients. *Can J Cardiol* 2003;19(suppl A):248A.
39. Chow CM, Yan AT, Yan R, Tan M, Adams GS, Lahey K, Fitchett DH, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Admission and Follow-Up ECG Classifications of Acute Coronary Syndromes: A Tale of Two Systems (ST versus Q Wave Status). *Can J Cardiol* 2003;19(suppl A):125A.
40. Yan R, Yan AT, Tan M, Chow CM, Fitchett DH, Ervin FL, Martin H, Cha JYM, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Age-related Differences In Clinical Characteristics, Management And One-year Outcome Of Patients With Acute Coronary Syndrome: Insights From The Canadian Acute Coronary Syndromes Registry. *Can J Cardiol* 2003;19(suppl A):256A.
41. Yan R, Yan AT, Tan M, Chow CM, Zaltzman JS, Pearce S, Fitchett DH, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Renal Dysfunction In Patients With Acute Coronary Syndromes Is Associated With Higher Risks of Death and Myocardial Infarction At One-year Follow-up. *Can J Cardiol* 2003;19(suppl A):260A.
42. Yan AT, Yan R, Tan M, Fitchett D, Chow DM, Hui W, Kvill L, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Underutilization of Key Secondary Prevention Therapies One Year Following an Acute Coronary Syndrome in Canada. *Can J Cardiol* 2003;19(suppl A):207A.
43. Yan R, Yan AT, Tan M, Fitchett DH, Chow CM, Abramson BL, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Lifestyle Modification and Cardiac Rehabilitation Following Acute Coronary Syndromes in Canada: One-year Results from the Lifestyle Substudy of the Canadian ACS Registry. *Can J Cardiol* 2003;19(suppl A):258A.

Canadian ACS Registries

ABSTRACTS - CONTINUED

44. Yan AY, Jong P, Yan R, Tan M, Kuritzky RA, Drozkiak L, Chow CM, Fitchett D, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Risk Scores Derived From Clinical Trials Do Not Apply To ““Real World”” Canadian Acute Coronary Syndrome . *Can J Cardiol* 2003;19(suppl A):256A.
45. Yan R, Yan AT, Chow CM, Leiter LA, Tan M, Fowlis R, Janzen I, Fitchett DH, Langer A, Goodman SG, for the Canadian Acute Coronary Syndrome Registry Investigators. Diabetic Patients With Acute Coronary Syndromes Were Under-treated And Had Worse One-year Mortality. *Can J Cardiol* 2003;19(suppl A):256A.
46. Yan R, Tan M, Langer A, Goodman S. Lifestyle modification and cardiac rehabilitation following acute coronary syndrome in Canada - one-year results from the life-style substudy of the Canadian Acute Coronary Syndromes Registry. *Clin Invest Med* 2003;26:89.
47. Yan R, Yan A, Tan M, Langer A, Goodman S. Adherence to secondary prevention therapies following acute coronary syndrome: one-year results from the Canadian Acute Coronary Syndromes Registry. *Clin Invest Med* 2003;26:91.
48. Yan AT, Goodman SG, Tan M, Fitchett D, Chow C-M, Langer A for the Canadian ACS Registry Investigators. Adherence to secondary prevention therapies following acute coronary syndromes: one-year results from the Canadian Acute Coronary Syndrome Registry. *J Am Coll Cardiol* 2003;41(suppl A):382A .
49. Yan A, Goodman SG, Tan M, Fitchett D, Chow CM, Lai K, Langer A, for the Canadian ACS Registry Investigators. Management and outcomes of patients with acute coronary syndromes: one year results from the Canadian Acute Coronary Syndrome Registry. *JACC* 2003 (in press). *J Am Coll Cardiol* 2003;41(suppl A):349A.
50. Chow CM, Goodman SG, Tan M, Greening-Aitken C, Witt I (deceased), Chisholm P, Ashton T, Arsenault B, Gupta S, Langer A. Regional differences in the outcomes, risk factors and demographics among patients with acute myocardial infarction: insights from the Canadian ACS Registry. *Can J Cardiol* 2002;18(suppl B):142B.
51. Yan A, Goodman SG, Tan M, Greening-Aitken C, Chow CM, Fitchett D, Lai K, Johnston D, Stensland J, Brossoit R, Robert C, Langer A. Management and outcomes of patients following acute coronary syndromes (ACS): one year follow-up from the Canadian ACS Registry. *Can J Cardiol* 2002;18(suppl B):152B.
52. Goodman SG, Fitchett D, Tan M, Spindler C, Timothee JR, Racicot D, Cloutier L, McAvinue T, Dorion D, Langer A, for the Canadian Acute Coronary Syndromes Registry Group. Management of acute coronary syndromes (ACS) in Canada: anti-platelet/thrombotic therapy in the first 24 hours. *Can J Cardiol* 2001;17(suppl C):228C.
53. Goodman SG, Tan M, Spindler C, Tremblay B, Darveau C, Lauzon C, Ouimet F, Langer A, for the Canadian Acute Coronary Syndromes Registry Group, Toronto, Quebec City and Thetford Mines. Secondary prevention following acute coronary syndromes in Canada: an evidence-based approach? *Can J Cardiol* 2001;17(suppl C):166C-167C.
54. Goodman SG, Tan M, Spindler C, Walker M, Churchill C, Skarpinsky B, Constance C, Maltais M, Langer A, for the Canadian Acute Coronary Syndromes Registry Group, Toronto, Prince Albert, and Montreal. Coronary angiography and revascularization in acute coronary syndromes (ACS): What the Canadian ACS Registry reveals about “real world” management during index hospitalization. *Can J Cardiol* 2001;17(suppl C):228C.

GRACE Registry

MANUSCRIPTS

1. Tan NS, Goodman SG, Yan RT, Elbarouni B, Budaj A, Fox KAA, Gore JM, Brieger D, López-Sendón J, Langer A, van de Werf F, Steg G, Yan AT. Comparative prognostic value of T-wave inversion and ST-segment depression on the admission electrocardiogram in non-ST-segment elevation acute coronary syndromes. *Am Heart J* 2013;166:290-7.
2. Bajaj RR, Goodman SG, Yan RT, Bagnall AJ, Gyenes G, Welsh RC, Eagle KA, Brieger D, Ramanathan K, Grondin FR, Yan AT. Treatment and Outcomes of Patients with Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions (Insights from the Canadian GRACE and CANRACE). *Am J Cardiol* 2013;111:202-07.
3. Elbarouni B, Banihashemi SB, Yan RT, Welsh RC, Kornder JM, Wong GC, Anderson FA, Spencer FA, Grondin FR, Goodman SG, Yan AT. Temporal patterns of lipid testing and statin therapy in acute coronary syndrome patients: The Canadian GRACE Experience. *Am J Cardiol* 2012;109:1418-24.
4. Amad H, Yan AT, Yan RT, Huynh T, Gore JM, Montalescot G, DeYoung JP, Gallo R, Rose B, Steg PG, Goodman SG. The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes: Insights from the Global Registry of Acute Coronary Events (GRACE). *Can J Cardiol* 2012;28(1):48-53.
5. Czarnecki A, Welsh RC, Yan RT, DeYoung JP, Gallo R, Rose B, Grondin FR, Kornder JM, Wong GC, Fox KAA, Gore JM, Goodman SG, Yan AT, on behalf of the Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Reperfusion strategies and outcomes of ST-Segment elevation myocardial infarction patients in Canada: Observations from The Global Registry Of Acute Coronary Events (GRACE). *Can J Cardiol* 2012;28(1):40-7.
6. Poon S, Goodman SG, Yan RT, Bugiardini R, Bierman AS, Eagle KA, Johnston N, Huynh T, Grondin FR, Schenck-Gustafsson K, Yan AT, on behalf of the Canadian Acute Coronary Syndrome Registries I and II, and the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Bridging the gender gap: Insights from a contemporary analysis of sex-related differences in the treatment and outcomes of patients presenting with acute coronary syndromes. *Am Heart J* 2012;163:66-73.
7. Elbarouni B, Ismaeil N, Yan RT, Fox KAA, Connelly KA, Baer C, DeYoung JP, Gallo R, Ramanathan K, Pesant Y, Leiter LA, Goodman SG, Yan AT, on behalf of the Canadian Acute Coronary Syndrome Registries I and II, and the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for non ST elevation acute coronary syndrome (NSTE-ACS). *Am Heart J* 2011;162:347-355.e1.
8. Edwards J, Goodman SG, Yan RT, Welsh RC, Kornder JM, De Young JP, Chauret D, Picard JP, Eagle KA, Yan AT, for the Canadian Global Registry of Acute Coronary Events (GRACE) and Canadian Registry of Acute Coronary Events (CANRACE) Investigators. Has the COMMIT Trial of early beta blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). *Am Heart J* 2011;161:291-297.
9. Elbarouni B, Elmanfud O, Yan RT, Fox KAA, Kornder JM, Rose R, Spencer FA, Welsh RC, Wong GC, Goodman SG, Yan AT. Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. *Am Heart J* 2010;160:420-7.
10. Ko DT, Newman AM, Alter DA, Austin PC, Chiu M, Cox JI, Goodman SG, Tu JV, for the Canadian Cardiovascular Outcomes Research Team. Secular Trends in Acute Coronary Syndrome Hospitalization from 1994 to 2005. *Can J Cardiol* 2010;26:129-34.
11. Lee TC, Goodman SG, Yan RT, Grondin FR, Welsh RC, Rose B, Gyenes B, Zimmerman RH, Brossoit R, Saposnik G, Yan AT. Disparities in Management Patterns and Outcomes of Non-ST Elevation Acute Coronary Syndrome Patients With and Without Prior History of Cerebrovascular Disease. *Am J Cardiol* 2010;105:1083-1089.
12. Jerzkiewicz S, Goodman SG, Yan RT, Grondin FR, Gallo R, Welsh RC, Lai K, Huynh T, Yan AT, on behalf of the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Evaluation of Left Ventricular Ejection Fraction in Non-ST-Segment Elevation Acute Coronary Syndromes and its Relationship to Treatment. *Am Heart J* 2010;159:605-11.

GRACE Registry

MANUSCRIPTS - CONTINUED

13. Wijeyesundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O'Flaherty M, Krahn M, Capewell S. Association of Temporal Trends in Risk Factors and Treatment Uptake with Coronary Heart Disease Mortality, 1994-2005. *JAMA* 2010;303:1841-7.
14. Elbarasi E, Goodman SG, Yan RT, Welsh RC, Kornder J, Wong GC, Déry JP, Anderson F, Gore JM, Fox KAA, Yan AT, on behalf of the Canadian Acute Coronary Syndrome Registries I and II (ACS I and ACS II) and Canadian Global Registry of Acute Coronary Events (GRACE/GRACE²) Investigators. Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. *Am Heart J* 2010;159:40-6
15. Spencer FA, Montalescot G, Fox KAA, Goodman SG, Granger CB, Goldberg RA, Oliveira GBF, Anderson FA, Eagle KA, FitzGerald G, Gore JM, and for the Global Registry of Acute Coronary Events (GRACE) Investigators. Delay to reperfusion in patients with acute myocardial infarction presenting to acute care hospitals. An international perspective. *Eur Heart J* 2010; doi: 10.1093/eurheartj/ehq057.
16. Fox KAA, Carruthers K, Steg PG, Avezum A, Granger CB, Montalescot G, Goodman SG, Gore JM, Quill AL, Eagle KA, for the GRACE Investigators. Has the frequency of bleeding changed over time for patients presenting with an acute coronary syndrome? The Global Registry of Acute Coronary Events. *Eur Heart J* 2010; 31(6):667-67.
17. Aragam KG, Tamhane UU, Kline-Rogers E, Li J, Fox KAA, Goodman SG, Eagle KA, Gurm HS. Does Simplicity Compromise Accuracy in ACS Risk Prediction? A Retrospective Analysis of the TIMI and GRACE Risk Scores. *PLoS ONE* 2009;4(11): e7947.
18. Yan RT, Yan AT, Allegrone J, Lopez-Sendon J, Granger C, Gore JM, Budaj A, Georgescu AA, Hassan A, Luchansky J, Van de Werf F, Goodman SG, on behalf of the Global Registry of Acute Coronary Events (GRACE) Electrocardiogram Substudy Group. Differences Between Local Hospital And Core Laboratory Interpretation Of The Admission Electrocardiogram In Patients With Acute Coronary Syndromes And Their Relation To Outcome. *Am J Cardiol* 2009. In Press.
19. Banihashemi B, Goodman SG, Yan RT, Welsh RC, Mehta SR, Montalescot G, Kornder JM, Wong GC, Gyenes G, Steg PG, Yan AT, for the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE²) Investigators. Underutilization of Clopidogrel and Glycoprotein IIb/IIIa Inhibitors in Non-ST Elevation Acute Coronary Syndrome Patients: The Canadian GRACE Experience. *Am Heart J* 2009;158:917-24.
20. Montalescot G, Brieger D, Eagle KA, Anderson FA, Jr, Lee MS, Steg PG, Avezum A, Goodman SG. Unprotected left main revascularization in patients with acute coronary syndromes. *Eur Heart J*. 2009;30:2308-2317. 10.1093/eurheartj/ehp353
21. Goodman SG, Huang W, Yan AT, Budaj A, Kennelly BM, Gore JM, Fox KAA, Goldberg RJ, Anderson FA, and for the Expanded Global Registry of Acute Coronary Events (GRACE²) Investigators. The expanded Global Registry of Acute Coronary Events: baseline characteristics, management practices, and hospital outcomes of patients with acute coronary syndromes. *Am Heart J*. 2009;158:193-201.e1-5.
22. Bagnall AJ, Goodman SG, Fox KAA, Yan RT, Gore JM, Cheema AN, Huynh T, Chauret D, Fitchett D, Langer A, Yan AT, for the Canadian Acute Coronary Syndrome Registry I and II Investigators and Canadian Global Registry of Acute Coronary Events (GRACE/GRACE²) Investigators. Influence of age on Use of Cardiac Catheterization and Associated Outcomes in Patients with Non-ST Elevation Acute Coronary Syndrome. *Am J Cardiol* 2009;103:1530-1536.
23. Elbarouni B, Goodman SG, Yan RT, Welsh RC, Kornder JM, DeYoung JP, Wong GC, Rose B, Grondin FR, Gallo R, Tan M, Casanova A, Eagle KA, Yan AT, on behalf of the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE²) Investigators. Validation of the GRACE Risk Score for In-Hospital Mortality in Acute Coronary Syndrome Patients in Canada. *Am Heart J* 2009;158(3):392-99.
24. Ruisi CP, Goldberg RJ, Kennelly BM, Goodman SG, Lopez-Sendon J, Granger CB, Avezum A, Eagle KA, FitzGerald G, Gore JM, on behalf of the GRACE investigators. Pulmonary Artery Catheterization In Patients with Acute Coronary Syndromes. *Am Heart J* 2009;158:170-6.

25. Yan AT, Steg PG, FitzGerald G, Feldman LJ, Eagle KA, Gore JM, Anderson FA, López-Sendón J, Gurfinkel EP, Brieger D, Goodman SG, for the GRACE Investigators. Recurrent Ischemia Across the Spectrum of Acute Coronary Syndromes: Prevalence and Prognostic Significance of (Re-)Infarction and ST-segment Changes in a Large Contemporary Registry. *Int J Cardiol* 2009; available online 28 May 2009, doi:10.1016/j.ijcard.2009.05.007.
26. LaBounty T, Gurm HS, Goodman SG, Montalescot G, Lopez-Sendon J, Quill A, Eagle KA, for the GRACE Investigators. Predictors and implications of Q-waves in ST-elevation acute coronary syndromes. *Am J Med* 2009;122:144-51.
27. Wong JA, Goodman SG, Yan RT, Wald R, Bagnall AJ, Welsh RC, Wong GC, Kornder J, Eagle KA, Steg PG, Yan AT, on behalf of the Canadian Acute Coronary Syndromes I and II, and Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Principal Author. Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. *Eur Heart J* 2009;30:549-57.
28. Swanson N, Montalescot G, Eagle KA, Goodman SG, Huang W, Brieger D, Devlin GP. Delay to angiography and outcomes following presentation with high-risk, non-ST elevation acute coronary syndromes (NSTE-ACS). Results from the Global Registry of Acute Coronary Events. *Heart* 2009;95:211-215.
29. Steg PG, Fox KAA, Eagle KA, Furman M, Van de Werf F, Montalescot G, Goodman SG, Avezum Á, Huang W, Gore JM, for the Global Registry of Acute Coronary Events (GRACE) Investigators. Mortality following placement of drug-eluting and bare-metal stents for ST-segment elevation acute myocardial infarction in the Global Registry of Acute Coronary Events. *Eur Heart J* 2009;30:321-29.
30. Rao R, Goodman SG, Yan RT, Spencer FA, Fox KA, DeYoung JP, Rose B, Grondin FR, Gallo R, Gore JM, Yan AT, on behalf of the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2). Temporal Trends and Patterns of Early Clopidogrel Use Across the Spectrum of Acute Coronary Syndromes. *Am Heart J* 2009;157:642-650.e1.
31. Jerzkiewicz S, Goodman SG, Yan RT, Welsh RC, Kornder J, DeYoung JP, Wong GC, Rose B, Grondin FR, Gallo R, Huang W, Gore JM, Yan AT, on behalf of the Canadian Global Registry of Acute Coronary Events (GRACE/GRACE2) Investigators. Temporal Trends in the Use of Invasive Cardiac Procedures for Non-ST-Segment Elevation Acute Coronary Syndromes According to Initial Risk Stratification. *Can J Cardiol* 2009;25:e370-e376.
32. Fox KAA, Anderson Jr, FAA, Goodman SG, Steg PG, Pieper K, Quill A, Gore JM, for the GRACE Investigators. Time course of events in acute coronary syndromes: implications for clinical practice from the GRACE registry. *Nature Clinical Practice Cardiovascular Medicine* 2008;5:580-589
33. Eagle KA, Nallamothu BK, Mehta RH, Granger CB, Steg PG, Van de Werf F, López-Sendón J, Goodman SG, Quill A, Fox KAA, for the Global Registry of Acute Coronary Events (GRACE) Investigators. Trends in acute reperfusion therapy for ST-segment elevation myocardial infarction from 1999 to 2006: we're getting better but we've got a long way to go. *Eur Heart J* 2008;29(5):609-17.
34. Yan RT, Yan AT, Granger CB, Lopez-Sendon J, Brieger D, Kennelly B, Budaj A, Steg PG, Georgescu AA, Hassan Q, MD, Goodman SG, on behalf of the Global Registry of Acute Coronary Events (GRACE) Electrocardiogram Substudy Group. Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. *Am J Cardiol* 2008;101:919-924.
35. Spencer FA, Goldberg RJ, Gore JM, Fox KAA, Avezum A, Agnelli G, Kritharides L, Anderson FA, Goodman SG, FitzGerald G, Allegrone J, Brieger D, GRACE Investigators. Comparison of Utilization of Statin Therapy at Hospital Discharge and Six-Month Outcomes in Patients With an Acute Coronary Syndrome and Serum Low-Density Lipoprotein ≥ 100 mg/dl Versus < 100 mg/dl. *Am J Cardiol* 2007;100:913-918.

GRACE Registry

MANUSCRIPTS - CONTINUED

36. Nguyen MC, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, Budaj A, Gulba DC, Allegrone J, Brieger D, for the GRACE Investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? *Eur Heart J* 2007; 28(14):1717-22.
37. Goldberg RJ, Spencer FA, Steg PG, Flather M, Gurfinkel EP, Kennelly BM, Goodman SG, Dedrick R, Gore JM, for the GRACE Investigators. Increasing use of single and combination medical therapy in patients hospitalized for acute myocardial infarction in the 21st century: a multinational perspective. *Arch Int Med* 2007;167(16):1766-73.
38. Fox KAA, Steg PG, Eagle KA, Goodman SG, Anderson FA, Granger CB, Flather MD, Budaj A, Quill A, Gore JM, for the GRACE Investigators. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes. Temporal Trends – 1999 to 2006. *Global Registry of Acute Coronary Events. JAMA* 2007;297:1892-1900.
39. Yan A, Yan R, Kennelly B, Anderson F, Budaj A, Lopez-Sendon J, Brieger D, Allegrone J, Steg PG, Goodman SG. Relationship of ST Elevation in Lead aVR with Angiographic Findings and Outcome in Non-ST Elevation Acute Coronary Syndromes. *Am Heart J* 2007;154:71-8.
40. Yan RT, Yan AT, Allegrone J, Lopez-Sendon J, Granger CB, Gore JM, Budaj A, Georgescu AA, Hassan Q, Luchansky J, Van de Werf F, Goodman SG. Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes are Associated with Worse Outcome. *Am J Cardiol* 2007;100:169-74.
41. Steg PG, Lopez-Sendon J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA, Himbert D, Allegrone J, Van de Werf F. External Validity of Clinical Trials in Acute Myocardial Infarction. *Arch Int Med* 2007;167:68-73.
42. Brieger D, Van de Werf F, Avezum A, Montalescot G, Kennelly BM, Granger CB, Goodman SG, Dabbous OH, Agnelli G, for the GRACE Investigators. Interactions Between Heparins, Glycoprotein IIb/IIIa Antagonists, and Coronary Intervention. *The Global Registry of Acute Coronary Events. American Heart Journal* 2007;153:960-69.
43. Oliveira GBF, Avezum A, Anderson Jr FA, Budaj A, Dabbous OH, Goodman SG, Steg PG, Goldberg RJ, Brieger D, Fox KAA, Gore JM, Granger CB, for the GRACE Investigators. Use of proven therapies in non-ST-elevation acute coronary syndromes according to evidence-based risk stratification. *Am Heart J* 2007;153(4):493-499.
44. Fox KAA, Dabbous OH, Goldberg RJ, Pieper KS, Eagle KA, Van de Werf F, Avezum A, Goodman SG, Flather MD, Anderson Jr FA, Granger CB, for the GRACE Investigators. Prediction of the risk of death and myocardial infarction in the six months following presentation with ACS: a prospective, multinational, observational study (GRACE). *British Medical Journal* 2006;333:1091-94.
45. Fox KAA, Anderson Jr FA, Dabbous OH, Steg PG, López-Sendón J, Van de Werf F, Budaj A, Gurfinkel EP, Goodman SG, Brieger D, on behalf of the GRACE Investigators. Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? *The Global Registry of Acute Coronary Events (GRACE). Heart* 2007;93(2):177-82.
46. Goodman SG, Steg PG, Eagle KA, Fox KAA, Lopez-Sendon J, Montalescot G, Budaj A, Kennelly BM, Gore JM, Allegrone J, Granger CB, Gurfinkel EP. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: Lessons from the Global Registry of Acute Coronary Events (GRACE). *Am Heart J* 2006;151:654-660.
47. Van de Werf F, Gore JM, Avezum A, Gulba DC, Goodman SG, Budaj A, Brieger D, White K, Fox KAA, Eagle KA, Kennelly BM, for the GRACE Investigators. Access to catheterisation facilities in patients admitted with acute coronary syndrome: multinational registry study. *British Medical Journal* 2005;330:441.

48. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, Goodman SG, Granger CB, Steg PG, Gore JM, Budaj A, Avezum A, Flather MD, Fox KAA, for the GRACE Investigators. A validated prediction model for all forms of acute coronary syndromes: estimating the risk of six-month post-discharge death in the global registry of acute coronary events (GRACE). *JAMA* 2004;291:2727-33.
49. Brieger D, Eagle KA, Goodman SG, Steg PG, Budaj A, White K, Montalescot G, for the GRACE Investigators. Acute coronary syndromes without chest pain: an underdiagnosed and undertreated high-risk group. Insights from the Global Registry of Acute Coronary Events (GRACE). *Chest* 2004;126:461-469.
50. Eagle KA, Kline-Rogers E, Goodman SG, Gurfinkel EP, Avezum A, Flather MD, Granger CG, Erickson S, White K, Steg PG. Adherence to Evidence-Based Therapies After Discharge for Acute Coronary Syndromes. An Ongoing, Prospective, Observational Study. *Am J Med* 2004;117:73-81.
51. Budaj A, Brieger D, Steg PG, Goodman SG, Fox KAA, Avezum A, Cannon CP, Mazurek T, Flather M, Dabbous OH, Van de Werf F, for the GRACE Investigators. Global patterns of use of antithrombotic and antiplatelet therapy in patients with acute coronary events. Insights from the Global Registry of Acute Coronary Events (GRACE). *Am Heart J* 2004;146:999-1006.
52. Goldberg RJ, Currie K, Sadiq I, Brieger D, Steg PG, Goodman SG, Gore JM. Six-month outcomes in a multinational registry of patients hospitalized with an acute coronary syndrome (The Global Registry of Acute Coronary Events [GRACE]). *Am J Cardiol* 2004;93:288-93.
53. Furman MI, Gore JM, Anderson FA, Budaj A, Goodman SG, Avezum A, López-Sendón J, Klein W, Mukherjee D, Eagle K, Dabbous OH, Goldberg RJ, for the GRACE Investigators. Elevated Leukocyte Count and Adverse Hospital Events in Patients with Acute Coronary Syndromes: Findings from the Global Registry of Acute Coronary Events (GRACE). *Am Heart J* 2004;147:42-8.
54. Fox KAA, Goodman SG, Anderson FA, Granger CB, Moscucci M, Flather MD, Spencer F, Budaj A, Dabbous OH, Gore JM, on behalf of the GRACE Investigators. From guidelines to clinical practice: the impact of hospital and geographical characteristics on temporal trends in the management of acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2003;24:1414-24.
55. Granger CB, Goldberg RJ, Dabbous O, Pieper KS, Eagle KA, Cannon CP, Van de Werf F, Avezum A, Goodman SG, Flather MD, Fox KAA, for the GRACE investigators. Predictors of hospital mortality in the Global Registry of Acute Coronary Events. *Arch Intern Med* 2003;163:2345-2353.
56. Fox KAA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A. Management of acute coronary syndromes. Variations in practice and outcome: findings from the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2002;23:1177-1189.
57. Goldberg RJ, Steg PG, Granger CB, Jackson EA, Budaj A, Brieger D, Avezum A, Goodman SG. Extent of, and factors associated with, delay to hospital presentation in patients with acute coronary disease (The GRACE Registry). *Am J Cardiol* 2002;89(7):791-6.
58. Eagle KA, Goodman SG, Avezum A, Budaj A, Sullivan CM, Lopez-Sendon J, for the GRACE investigators. Practice variation and missed opportunities for reperfusion in ST-segment elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). *Lancet* 2002;359:373-77.
59. The GRACE Investigators. GRACE (Global Registry of Acute Coronary Events) project: A multinational registry of patients hospitalized with acute coronary syndromes. *Am Heart J* 2001;141:190-199.

GRACE Registry

ABSTRACTS

1. Tan NS, Goodman SG, Yan RT, Elbarouni B, Budaj A, Fox KAA, Gore JM, Brieger D, López-Sendón J, Langer A, van de Werf F, Steg G, Yan AT. Comparative prognostic value of T wave inversion and ST depression on the admission ECG in non-ST elevation acute coronary syndromes. Accepted for poster presentation at the Canadian Cardiovascular Congress, October 2013.
2. Li Q, Goodman SG, Polasek P, Lai K, Baer C, Gore JM, Goldberg RJ, Yan RT, Pinter A, Ahmad K, Kornder JM, Yan AT. Cardiac arrest in acute coronary syndromes: Insights from the Canadian Global Registry of Acute Coronary Events. *Can J Cardiol* 2012;28(5S):S134.
3. Nguyen T, Abramson BL, Galluzzi A, Tan M, Yan AT, Goodman SG, for the Canadian GRACE Investigators. Temporal trends and factors associated with referral for cardiac rehabilitation post-acute coronary syndrome: Insights from the Canadian Global Registry of Acute Coronary Events (GRACE). *Can J Cardiol* 2012;28(5S):S247.
4. Bajaj R, Goodman SG, Yan RT, Bagnall AJ, Gyenes G, Welsh RC, Eagle KA, Brieger D, Ramanathan K, Grondin FR, Yan AT. Real-world management and outcomes of patients with suspected acute coronary syndromes in relation to initial diagnostic impressions: Insights from the Canadian GRACE and CANRACE Studies. *Can J Cardiol* 2012;28(5S):S196.
5. Goodman SG, Huang W, Gore JM, Steg PG, Eagle KA, Anderson FA, Fox KAA. The late consequences of acute coronary syndromes: 2-year follow-up outcomes, procedures, and treatment of patients from the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2011;32(suppl 1):677.
6. Gyenes G, Yan AT, Tan M, Welsh RC, Fox KA, Grondin FR, DeYoung JP, Rose BF, Casanova A, Gallo R, Kornder JM, Wong GC, Goodman SG. Is waiting for a coronary angiogram on the weekend safe for non-ST-segment elevation myocardial infarction (NSTEMI) patients? Insights from the Canadian Global Registry of Acute Coronary Events. *Can J Cardiol* 2011;27(5S):S147-148.
7. Kornder JM, DeYoung JP, Welsh R, Goodman SG, Yan RT, Wong GC, Spencer FA, Grondin F, Yan AT. Lessons from CANRACE Registry. Care gaps in ACS in Canada: Medication adherence at hospital discharge and at six months. *Can J Cardiol* 2010;26(Suppl D):30D.
8. Elbarouni B, Hutchinson-Jaffe AB, Goodman SG, Yan RT, Baer C, Lai C, Eagle KA, Langer A, Rose BF, Wald R, Yan AT. Differences in the baseline characteristics and management of non-ST segment elevation myocardial infarction patients as a function of participation in clinical trials. *Can J Cardiol* 2010;26(Suppl D):55D.
9. Banihashemi B, Goodman SG, Yan RT, Welsh RC, Kornder JM, Wong GC, Anderson Jr FA, Spencer FA, Grondin FR, Yan AT. In-hospital lipid testing and statin therapy in Canadian acute coronary syndrome patients in the Global Registry of Acute Coronary Events: Increasing over time but still underused. *Can J Cardiol* 2010;26(Suppl D):31D.
10. Ali S, Goodman SG, Yan RT, Brieger D, Budaj A, Lopez-Sendon J, Fox FAA, Gore JM, Langer A, Steg PG, Van de Werf F, Yan AT. Prognostic significance of electrocardiographic left ventricular hypertrophy and associated ST-segment depression in non-ST elevation acute coronary syndrome. *Can J Cardiol* 2010;26(Suppl D):111D.
11. Amad H, Yan AT, Yan RT, Gore JM, Gallo R, DeYoung JP, Rose B, Montalescot B, Steg PG, Huynh T, Goodman SG. The association between prior use of aspirin and/or warfarin and the in-hospital management and outcomes in patients presenting with acute coronary syndromes. *Can J Cardiol* 2010;26(Suppl D):111D.
12. Yan AT, Elmanfud O, Yan RT, Elbarouni B, Wong GC, Kornder JM, Rose BF, Welsh RC, Goodman SG. Temporal trend of in-hospital major bleeding in Canadian patients with non-ST elevation acute coronary syndromes. *Can J Cardiol* 2009; 25(Suppl B):140B.
13. Ismaeil NH, Goodman SG, Yan RT, DeYoung JP, Gallo R, Baer C, Ramanathan K, Yan AT. Temporal changes in the management and outcome of Canadian diabetic patients hospitalized for acute coronary syndrome (ACS). *Can J Cardiol* 2009; 25(Suppl B):133B.

14. Lee TC, Goodman SG, Yan RT, Grondin FR, Welsh RC, Rose B, Gyenes, Zimmerman RH, Brossoit R, Saposnik G, Yan AT. Disparities in management patterns and outcomes of non-ST elevation acute coronary syndrome patients with and without prior history of cerebrovascular disease. *Can J Cardiol* 2009; 25(Suppl B):116B.
15. Edwards J, Goodman SG, Yan RT, DeYoung JP, Kornder JM, Welsh RC, Chauret D, Picard JP, Yan AT. Has the COMMIT trial of early beta blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). *Can J Cardiol* 2009; 25(Suppl B):44B.
16. Welsh RC, Yan AT, Yan RT, Gallo R, Rose BF, Wong GC, Kornder JM, Grondin FR, DeYoung JP, Mehta SR, Goodman SG. Impact of prior CABG on reperfusion therapy in Canadian ST-elevation myocardial infarction (STEMI) patients: Insights from the Global Registry of Acute Coronary Events (GRACE). *Can J Cardiol* 2009; 25(Suppl B):132B.
17. Sibbald M, Yan AT, Huang W, Fox KA, Gore JM, Steg PG, Eagle KA, Brieger D, Montalescot G, Goodman SG. Association between smoking and the effectiveness and safety of early clopidogrel use in acute coronary syndrome (ACS) patients: Insights from the Global Registry of Acute Coronary Events (GRACE). *Can J Cardiol* 2009;25(Suppl B):139B.
18. Wong JA, Goodman SG, Yan RT, Wald R, Gore J, Wong GC, Gallo R, Welsh RC, Grondin FR, Kornder JM, De Young P, Bagnall AJ, Rose B, Fox KAA, Yan AT, on behalf of ACS Registries & GRACE Investigators. Temporal Patterns in the Management of Non-ST Elevation Acute Coronary Syndromes in Patients With Renal Dysfunction and Associated Outcomes. *Can J Cardiol* 2008;24(suppl E):259E.
19. Welsh RC, Yan AT, Yan RT, De Young P, Rose B, Gallo R, Grondin FR, Kornder JM, Gore J, Wong GC, Fox KA, Goodman SG, on behalf of the GRACE, GRACE2 Investigators. Reperfusion Strategies And The Role Of Percutaneous Coronary Intervention In Canadian ST-Segment Elevation Myocardial Infarction Patients: Observations From The GRACE/GRACE2. *Can J Cardiol* 2008;24(suppl E):67E.
20. Yan RT, Goodman SG, Kornder JM, Gore J, Fox KA, Grondin FR, Wong GC, De Young P, Gallo R, Welsh RC, Rose B, Yan AT, on behalf of GRACE, GRACE2 Investigators. Prior Revascularization Is Associated With The Use Of An Invasive Strategy In Non-ST-Segment Elevation Acute Coronary Syndromes In Canada: Insights From GRACE. *Can J Cardiol* 2008;24(suppl E):260E.
21. Yan AT, Yan RT, Welsh RC, Gore J, Wong GC, Fox KA, De Young P, Grondin FR, Gallo R, Kornder JM, Rose B, Goodman SG, on behalf of Canadian GRACE, GRACE2 Investigators. Clopidogrel Use In Canadian Acute Coronary Syndrome Patients In The Global Registry Of Acute Coronary Events: Increasing Over Time But Still Underutilized. *Can J Cardiol* 2008;24(suppl E):327E.
22. Banihashemi B, Goodman SG, Yan RT, Fox KA, Wong GC, De Young P, Gallo R, Grondin FR, Welsh RC, Kornder JM, Gore J, Rose B, Yan AT, on behalf of GRACE, GRACE2 Registry Investigators. Underutilization Of Clopidogrel And Glycoprotein IIb/IIIa Inhibitors In Non-St-Segment Elevation Acute Coronary Syndrome Patients: The Canadian GRACE Experience. *Can J Cardiol* 2008;24(suppl E):325E.
23. Gore JM, Marre M, Steg PG, Brieger D, Quill A, Goodman SG, for the GRACE Investigators. Treatment and Outcome of Diabetic Patients with an Acute Coronary Syndrome: Has There Been any Improvement Over Time? The GRACE Registry. *J Am Coll Cardiol* 2008;51(Suppl A):A244.
24. LaBounty T, Gurm HS, Goodman SG, Montalescot G, Lopez-Sendon J, Quill A, Eagle KA. Predictors and Implications of Q-waves in ST-Elevation Myocardial Infarction: A Contemporary Perspective from the Global Registry of Acute Coronary Events. *Circulation* 2007;116(Suppl 2):II-526.
25. Yan AT, Yan RT, Welsh RC, Wong GC, Lornder JM, Rose B, Goodman SG. Validation of the Multinational, Registry-Derived GRACE Risk Score in a Broad Spectrum of Acute Coronary Syndrome Patients in Canada. *Can J Cardiol* 2007;23(Suppl C):98C.

GRACE Registry

ABSTRACTS - CONTINUED

26. Yan RT, Yan AT, Welsh RC, Wong GC, Kornder JM, Rose B, Goodman SG. Coronary Angiography and Revascularization are Paradoxically Directed Towards Lower Risk Non-ST Elevation Acute Coronary Syndrome Patients: Contemporary Insights from GRACE & GRACE 2 in Canada. *Can J Cardiol* 2007;23(Suppl C):121C.
27. Wang T, Goodman SG, Flather MD, Gurfinkel EP, Quill AL, Menon V. No impact of drug-eluting stents on rates of in-hospital coronary artery bypass surgery following non-ST-segment elevation myocardial infarction. *The GRACE registry. Eur Heart J* 2007;28(Suppl 1):735.
28. Gore J, Fox KA, Eagle KA, Furman M, Van De Werf F, Montalescot G, Goodman SG, Avezum A, Huang W, Steg PG. Increased all-cause mortality at 2 year follow-up after PCI with drug-eluting stents vs bare metal stents in acute coronary syndromes: the Global Registry of Acute Coronary Events experience. *Eur Heart J* 2007 (in press).
29. Devlin G, Swanson N, Silverstone A, Montalescot G, Eagle KA, Goodman SG, Huang W, Brieger D. Do treatment delays influence outcomes following presentation with non-ST elevation acute coronary syndrome? *The GRACE Registry. Eur Heart J* 2007;28(Suppl 1):65.
30. Petrina M, Eagle KA, Lopez-Sendon J, Steg PG, Fox KA, Stiles M, Quill A, Goodman SG, for the GRACE Investigators. The Prognostic Value of the 12-Lead Electrocardiogram (ECG) in Patients Presenting with Acute Coronary Syndromes (ACS): Insights from the Global Registry of Acute Coronary Events (GRACE) ECG Substudy. *J Am Coll Cardiol* 2007;49(Suppl A):187A.
31. Jolly S, Goodman SG, Shenkman H, Brieger D, Fox KA, Yan AT, Anderson FA, Allegrone J, Eagle KA. Quantitative Troponin Predicts Cardiogenic Shock, Sustained Ventricular Arrhythmias, Cardiac Arrest and Reinfarction in Non-ST Elevation Acute Coronary Syndromes. *The GRACE Registry. Can J Cardiol* 2006;22(Suppl D):166D.
32. Yan AT, Yan RT, Allegrone J, Kennelly B, Anderson F, Steg PG, Goodman SG. Prevalence and Prognostic Significance of ST Elevation In aVR in Patients with Non-ST Elevation Acute Coronary Syndromes. *Can J Cardiol* 2006; 22(Suppl D):193D.
33. Jolly S, Goodman SG, Shenkman H, Brieger D, Fox KA, Yan AT, Anderson FA, Allegrone J, Eagle KA. Quantitative Troponin Predicts Cardiogenic Shock, Sustained Ventricular Arrhythmias, Cardiac Arrest and Reinfarction in Non-St Elevation Acute Coronary Syndromes. *The Grace Registry. Eur Heart J* 2006;27(Suppl):1447.
34. Lopez-Sendon JL, Goodman SG, Steg PG, Brieger D, Eagle K, Granger C, Gurfinkel E, Dedrick R, Gore JM, for the GRACE Investigators. Heparin Therapy During Fibrinolysis in ST-Segment Elevation Myocardial Infarction: Registry Data Support Clinical Trial Results. *Circulation* 2006;114(Suppl):II-863.
35. Nguyen M, Lim YL, Walton A, Lefkovits J, Agnelli G, Goodman SG, Budaj A, Gulba DC, Allegrone J, Brieger D, for the GRACE Investigators. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent? *J Am Coll Cardiol* 2006;47(Suppl A):252A.
36. Eagle KA, Mehta RH, Nallamothu BK, Granger CB, Steg PG, Van de Werf F, Lopez-Sendon J, Goodman SG, Allegrone J, Fox KA, for the GRACE Investigators. Global reperfusion therapy in acute myocardial infarction – 1999 to 2004: We’re getting better, but we have a long way to go. *The Global Registry of Acute Coronary Events. Circulation* 2005; 112(Suppl):II-794.
37. Petersen JL, Reist CJ, Col JJ, Anderson FA, Fox KAA, Goodman SG, Langer A, Ferguson JJ. Patient characteristics and clinical events from GRACE and SYNERGY: differences persist in utilization of standard therapies in clinical practice. *Circulation* 2005; 112(Suppl):II-776
38. Fox KA, Anderson FA, Goodman SG, Dabbous OH, Gore JM, on behalf of the GRACE Investigators. Time course of events following presentation with acute coronary syndrome: observations from 33,402 patients in the Global Registry of Acute Coronary Events. *Eur Heart J* 2005;26 (Abstr Suppl):118.
39. Yan AT, Goodman SG, Kennelly BM, Anderson FA, Allegrone J, Steg PG, on behalf of the GRACE Investigators. Prevalence and prognostic significance of ST elevation in aVR: Insights from the Global Registry of Acute Coronary Events Electrocardiographic Substudy. *Eur Heart J* 2005;26 (Abstr Suppl):282.

40. Goodman SG, Yan AT, Allegrone J, Lopez-Sendon J, Granger CB, Gore JM, Budaj A, Georgescu AA, Hassan Q, Luchansky J, Van de Werf F, for the GRACE ECG Substudy Investigators. Disagreement in the Interpretation of the Admission Electrocardiogram in Acute Coronary Syndromes and Association With Clinical Outcome: Real-World Insights From GRACE. *J Am Coll Cardiol* 2005;45(Suppl A):240A.
41. Spencer FA, Gore JM, Oliveira G, Montalescot G, Fox KAA, Goodman SG, Malone S, Granger CB, on behalf of the GRACE Investigators. Determinants of delay in patients undergoing primary angioplasty for ST-segment elevation myocardial infarction. The Global Registry of Acute Coronary Events. *Eur Heart J* 2005;26 (Abstr Suppl):621.
42. Steg PG, López-Sendón J, Lopez de Sa E, Goodman SG, Gore JM, Anderson FA Jr, Himbert D, Allegrone J, Van de Werf F, for the GRACE Investigators. Comparison of patients with ST-segment elevation myocardial infarction enrolled in fibrinolytic drug trials with trial-eligible and trial-ineligible patients. Findings from the Global Registry of Acute Coronary Events. *Circulation* 2004;110(Suppl III):III-783.
43. Jelinek M, Goodman SG, López-Sendón J, Gurfinkel E, White K, Brieger D. The impact of the new definition of acute myocardial infarction on patients discharged with unstable angina pectoris -- six month outcomes: the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2003;24 (Abstr Suppl):723.
44. Fox KAA, Anderson F, Goodman SG, Budaj A, Granger C, Flather M, Spencer F, Moscucci M, Dabbous O, Gore JM. Influence of guidelines and results from major clinical trials on medical practice: findings from the Global Registry of Acute Coronary Events (GRACE). *J Am Coll Cardiol* 2003;41(suppl A):518A
45. Goodman S, Granger CB, White K, Brieger D, Budaj A, Dabbous OH, Steg PG, on behalf of the GRACE Investigators. Acute coronary syndrome patients with ST segment depression have substantial mortality rates but undergo less aggressive management strategies: insights from the Global Registry of Acute Coronary Events (GRACE). *J Am Coll Cardiol* 2003;41(suppl A):325A.
46. Eagle KA, Lim MJ, Budaj A, Dabbous OH, Pieper K, Goodman SG, Granger CB, Steg PG, Gore JM, Fox KA. A robust prediction model for all forms of acute coronary syndromes: estimating the risk of in-hospital death and myocardial infarction in the Global Registry of Acute Coronary Events (GRACE). *J Am Coll Cardiol* 2003;41(suppl A):353A.
47. Brieger D, Eagle KA, Goodman SG, Lopez-Sendon J, Steg PHG, Budaj A, White K, Montalescot G, on behalf of the GRACE investigators. Atypical presentation of acute coronary syndromes independently predicts myocardial infarction and increased in-hospital mortality: insights from the GRACE registry. *Eur Heart J* 2002;23(Abstr Suppl):105.
48. Steg PHG, Feldman LJ, Brami M, Vahanian A, Eagle KA, López-Sendón J, Dabbous O, Goodman SG, on behalf of the GRACE investigators. Recurrent ischaemia in acute coronary syndromes: differential impact of electrocardiographic changes on outcomes. *Eur Heart J* 2002;23(Abstr Suppl):588.
49. Fox KAA, Goldberg RJ, Pieper K, Cannon CP, Van de Werf F, Goodman SG, Dabbous O, Granger CB, on behalf of the GRACE investigators. Predictors of in-hospital mortality in the global registry of acute coronary events (GRACE). *Eur Heart J* 2002;23(Abstr Suppl):626.
50. Furman MI, Davidson MC, Anderson FA, Jr, Budaj A, Goodman SG, Avezum A, Lopez-Sendon J, Klein W, Gore JM. Relationship between elevated leukocyte count and hospital clinical events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events. *Circulation* 2001;104(suppl II):II-650.
51. Gurfinkel EP, Duroto E, Lopez de Sa E, Avezum A, Sadiz I, Klein W, Goldberg RJ, Johnson J, Goodman SG. 'Necrosette' infarction versus traditionally defined non-ST-segment elevation myocardial infarction (NSTEMI) and in-hospital course. Findings from the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2001;22(Suppl):519.
52. Van de Werf F, Avezum A, Gulba D, Goodman S, Budaj A, Brieger D, Gore J, Cannon C, White K, Kennelly B. Interventional procedures and in-hospital outcomes in patients with acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). *Eur Heart J* 2001;22(Suppl):617.

GRACE Registry

ABSTRACTS - CONTINUED

53. Goodman S, Johnson J, Sullivan C, Steg PHG, Eagle K, Fox KAA, Lopez-Sendon J, Montalescot G, Budaj A, Kennelly B, Gore J, for the GRACE Investigators. What is an MI? Prospective analysis of the diagnostic and prognostic impact of adding troponins to the definition of myocardial infarction. *J Am Coll Cardiol* 2001;37(suppl A):358A.

INTERACT

MANUSCRIPTS

1. Rousseau M, Yan RT, Tan M, Lefkowitz CJ, Casanova A, Fitchett D, Jolly SS, Langer A, Goodman SG, Yan AT, for the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Relation between hemoglobin level and recurrent myocardial ischemia in acute coronary syndromes detected by continuous electrocardiographic monitoring. *Am J Cardiol* 2010;106:1417-1422.
2. Yan AT, Yan RT, Huynh T, DeYoung P, Weeks A, Fitchett DH, Langer A, Goodman SG, for the INTERACT Investigators. Bleeding and Outcome in Acute Coronary Syndrome: Insights from Continuous ECG Monitoring in the INTERACT Trial. *Am Heart J* 2008;156(4):769-775.
3. Murphy SA, Antman E, Van de Werf F, Goodman SG, Mahaffey K, Menown I, Cohen M, Gibson CM. Efficacy and Safety of the Low-Molecular Weight Heparin Enoxaparin Compared with Unfractionated Heparin across the Acute Coronary Syndrome Spectrum: A Meta-Analysis. *Eur Heart J* 2007;28:2077-86.
4. Yan AT, Yan RT, Tan M, Senaratne M, Fitchett DH, Langer A, Goodman SG. Long-term Prognostic Value and Therapeutic Implications of Continuous ST-Segment Monitoring in Acute Coronary Syndromes. *Am Heart J* 2007;153:500-506.
5. Jolly S, Tan M, Mendelsohn A, Fitchett D, Armstrong PW, Langer A, Goodman SG. Comparison of Effectiveness of Enoxaparin versus Unfractionated Heparin to Reduce Silent and Clinically Apparent Acute Myocardial Infarction in patients presenting with non-ST Segment Elevation Acute Coronary Syndrome. *Am J Cardiol* 2007;99:186-188.
6. Fitchett D, Langer A, Armstrong PW, Tan M, Mendelsohn A, Goodman SG. Randomized evaluation of the efficacy of enoxaparin versus unfractionated heparin in high risk patients with non-ST segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Long term results of the INTERACT trial. *Am Heart J* 2006;151:373-379.
7. Goodman SG. Enoxaparin and glycoprotein IIb/IIIa inhibition in non-ST-elevation acute coronary syndrome: Insights from the INTERACT trial. *Am Heart J* 2005;149(Suppl):S73-80.
8. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A, for the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin vs unfractionated heparin in high-risk pts with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. *Circulation* 2003;107:238-244.

INTERACT

ABSTRACTS

1. Rousseau M, Yan RT, Goodman SG, Lefkowitz CJ, Casanova A, Fitchett DH, Jolly SS, Langer A, Tan M, Yan AT. The relationship between hemoglobin level and recurrent ischemia in acute coronary syndromes: Insights from continuous ECG monitoring. *Can J Cardiol* 2010;26(Suppl D):111D.
2. Yan AT, Yan RT, Tan M, Huynh T, Fitchett DH, Langer A, Goodman SG. Bleeding and Outcome in Acute Coronary Syndrome: Insights from Continuous ECG Monitoring in the INTERACT Trial. *Circulation* 2007;116(Suppl 2):11-481.
3. Yan AT, Yan RT, Tan M, Huynh T, Fitchett DH, Langer A, Goodman SG. Bleeding and Outcome in Acute Coronary Syndrome: Insights from Continuous ECG Monitoring in the INTERACT Trial. *Can J Cardiol* 2007;23(Suppl C):223C.
4. Yan AT, Yan RT, Tan M, Mendelsohn A, Jolly S, Fitchett DH, Langer A, Goodman SG. Long-term Prognostic Value and Therapeutic Implications of Continuous ST-segment Monitoring in Acute coronary Syndrome. *J Am Coll Cardiol* 2007;49(Suppl A):204A.
5. Yan AT, Yan RT, Tan M, Mendelsohn A, Jolly S, Fitchett D, Langer A, Goodman SG. Global Registry of Acute Coronary Events (Grace) Risk Score and Continuous ST-Segment Monitoring Provide Complementary Long-Term Prognostic Information in Patients with Non-ST Elevation Acute Coronary Syndromes. *Can J Cardiol* 2006; 22(Suppl D):167D.
6. Yan AT, Yan RT, Tan M, Armstrong PW, Granger CB, Dabbous O, Fox KA, Eagle KA, Huynh T, Fitchett DH, Langer A, Goodman SG. Enoxaparin is Consistently More Effective Than Unfractionated Heparin Across the Spectrum of Risk in Non-ST Elevation Acute Coronary Syndrome Patients: Insights from the INTERACT Trial. *JACC* 2005;45(Suppl A):230A.
7. Yan AT, Yan RT, Tan M, Armstrong PW, Granger CB, Dabbous O, Fox KA, Eagle KA, Huynh T, Fitchett DH, Langer A, Goodman SG. Enoxaparin is Consistently More Effective Than Unfractionated Heparin Across the Spectrum of Risk in Non-ST Elevation Acute Coronary Syndrome Patients: Insights from the INTERACT Trial. *Can J Cardiol* 2004;20(Suppl D):124.

TRANSFER AMI Study

MANUSCRIPTS

1. Lavi S, Cantor WJ, Casanova A, Tan MK, Yan AT, Džavík V, Fitchett D, Cohen EA, Borgundvaag B, heffernan M, Ducas J, Goodman SG, on behalf of the TRANSFER-AMI Trial Investigators. Efficacy and safety of enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of acute ST-segment elevation myocardial infarction. Insights from the TRANSFER-AMI trial. *Am Heart J* 2012;163(2):176-181.e2.
2. Bhan V, Cantor WJ, Yan RT, Mehta SR, Morrison LJ, Heffernan M, Fitchett D, Džavík V, Ducas J, Borgundvaag B, Cohen EA, Goodman SG, Yan AT, on behalf of the TRANSFER-AMI Investigators. Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from TRANSFER-AMI. *Am Heart J* 2012;164:343-50.
3. Yan AT, Yan RT, Cantor WJ, Borgundvaag B, Cohen EA, Fitchett DH, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG, for the TRANSFER-AMI Investigators. Relationship between risk stratification at admission and treatment effects of early invasive management following fibrinolysis: Insights from the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). *Eur Heart J* 2011;32(16):1994-2002.
4. Borgia F, Goodman SG, Halvorsen S, Cantor WJ, Piscione F, LeMay MR; Fernandez-Aviles F, Sanchez PL, Dimopoulos K, Scheller B; Armstrong PW; Di Mario C. Early routine percutaneous coronary intervention after fibrinolysis versus standard therapy in ST-segment elevation myocardial infarction: A meta-analysis. *Eur Heart J* 2010;31:2156–2169.
5. Cantor WJ, Fitchett D, Borgundvaag B, Ducas J, Heffernan M, Cohen EA, Morrison LJ, Langer A, Dzavik V, Mehta S, Lazzam C, Schwartz B, Casanova A, Goodman SG, on behalf of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) Investigators. Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction. *N Engl J Med* 2009;360:2705-18.
6. Cantor WJ, Fitchett D, Borgundvaag B, Heffernan M, Cohen EA, Morrison LJ, Langer A, Mehta S, Lazzam C, Schwartz B, Dzavik V, Goodman SG. Rationale and design of the Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). *Am Heart J* 2008;155:19-25.
7. Cantor WJ, Burstein J, Choi R, Heffernan M, Dzavik V, Lazzam C, Duic M, Fitchett D, Tan M, Wawrzyniak J, Kassam S, Dhingra S, Morrison LJ, Langer A, Goodman SG. Transfer for urgent percutaneous coronary intervention early after thrombolysis for ST-elevation myocardial infarction: The TRANSFER AMI pilot feasibility study. *Can J Cardiol* 2006;22:1121-1126.

TRANSFER AMI Study

ABSTRACTS

1. Yan AT, Yan RT, Mehta SR, Morrison LJ, Cantor WJ, Heffernan M, Fitchett D, Dzavik V, Ducas J, Lazzam C, Borgundvaag B, Cohen EA, Goodman SG. Efficacy of early invasive management post-fibrinolysis in men versus women with ST-elevation myocardial infarction: A subgroup analysis from TRANSFER-AMI. *Can J Cardiol* 2011;27(5S):S152-153.
2. Goodman SG, Cantor WJ, Borgundvaag B, Fitchett D, Dzavik V, Ducas J, Heffernan M, Cohen EA, Yan AT, Lavi S, for the TRANSFER AMI Investigators. Enoxaparin compared with unfractionated heparin in the pharmacoinvasive management of ST elevation myocardial infarction - Insights from the TRANSFER AMI Trial. *J Am Coll Cardiol* 2011;57(14):E987.
3. Yan AT, Cantor WJ, Yan RT, Borgundvaag B, Cohen EA, Dzavik V, Ducas J, Tan M, Casanova A, Goodman SG. Risk stratification at admission to identify ST-segment elevation myocardial infarction patients receiving fibrinolysis who may benefit from early angioplasty: Insights from the Trial of Routine Angioplasty and Stenting after Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI). *Can J Cardiol* 2010;26(Suppl D):77D; *Circulation* 2010;122 (suppl 21):A15640.
4. Piscione F, Cantor WJ, Fernandez-Aviles F, Halvorsen S, LeMay M, Armstrong PW, Bruno S, Goodman SG, Dimopoulos K, Borgia F, Di Mario C. Early PCI after thrombolysis versus standard therapy in STEMI patients: a cumulative meta-analysis. *J Am Coll Cardiol* 2010;55(suppl A):A105.
5. Cantor WJ, Fitchett D, Borgundvaag B, Heffernan M, Cohen EA, Morrison LJ, Ducas J, Langer A, Mehta S, Lazzam C, Schwartz B, Dzavik V, Casanova A, Singh P, Goodman SG. Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) - Six Month Outcomes. *Circulation* 2008;118(Suppl 2):S1075.
6. Cantor WJ, Fitchett D, Borgundvaag B, Heffernan M, Cohen EA, Morrison LJ, Ducas J, Langer A, Mehta S, Lazzam C, Schwartz B, Dzavik V, Casanova A, Goodman SG. Trial of Routine ANgioplasty and Stenting After Fibrinolysis to Enhance Reperfusion in Acute Myocardial Infarction (TRANSFER-AMI) - Six Month Outcomes. *Can J Cardiol* 2008;24(Suppl E):348E.
7. Morrison LJ, Cantor WJ, Choi R, Heffernan M, Dzavik V, Lazzam C, Duic M, Fitchett D, Wawrzyniak J, Kassam SA, Goodman SG, Langer A. Infarction in Ontario - results of the TRANSFER-AMI pilot study. *Prehospital Emergency Care* January 2005;9(1):141.
8. Cantor WJ, Choi R, Heffernan M, Dzavik V, Lazzam C, Duic M, Fitchett D, Wawrzyniak J, Kassam S, Morrison LJ, Goodman SG, Langer A. Feasibility of facilitated PCI for ST-elevation myocardial infarction in Ontario – results of the TRANSFER-AMI pilot study. *Can J Cardiol* 2004;20(Suppl D):152D.

III CARDIO-METABOLIC

ACTFAST Study

MANUSCRIPTS

1. Gupta M, Martineau P, Tran T, Després J-P, Gaw A, de Teresa G, Farsang C, Gensini GF, Leiter LA, Blanco-Colio LM, Edigo J, Langer A. Low-density lipoprotein cholesterol and high-sensitivity C-reactive protein lowering with atorvastatin in patients of South Asian compared with European origin: Insights from the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) Study. Published on-line May 24, 2011.
2. Gensini GF, Gori AM, Dilaghi B, Rostagno C, Gaw A, Blanco-Colio LM, de Teresa E, Egido J, Farsang C, Leiter LA, Martineau P, Nozza A, Langer A, on behalf of the ACTFAST Investigators. Effect of atorvastatin on circulating hsCRP concentrations: A sub-study of the Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration (ACTFAST) study. *Internat J Cardiol* 2010;142:257-264.
3. Leiter LA, Langer A. Achieving Cholesterol Targets By Individualizing Starting Doses of Statin According to Baseline LDL-C and Coronary Heart Disease Risk Category: The CanACTFAST Study. *Can J Cardiol* 2009.
4. Ur E, Langer A, Rabkin SW, Calciu C-D, Leiter LA, on behalf of the CanACTFAST Study Investigators. Achieving cholesterol targets by individualizing starting doses of statin according to baseline LDL-C and coronary heart disease risk category: The CanACTFAST study. *CMAJ* 2009.
5. Moride Y, Hegele RA, Langer A, McPherson R, Miller DB, Rinfret S. Clinical and public health assessment of benefit-risk of statins in the primary prevention of coronary events: Resolved and unresolved issues. *Can J Cardiol* 2008;24(4):293-300.
6. Leiter LA, Martineau P, de Teresa E, Farsang C, Gaw A, Gensini GF, Langer A, on behalf of the ACTFAST 1 & 2 Investigators. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. *J Fam Prac* 2008;57(10):661-668.
7. Blanco-Colio LM, Martin-Ventura JL, Gómez-Guerrero C, Masramon X, de Teresa E, Farsang C, Gaw A, Gensini GF, Leiter LA, Langer A, Egido J. Adiponectin plasma levels are increased by atorvastatin treatment in subjects at high cardiovascular risk. *Eur J Pharmacol* 2008;586:259-265.
8. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini GF, Leiter LA, Langer A, Martineau P, Egido J, on behalf of the ACTFAST investigators. Atorvastatin decreases elevated soluble CD40L in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers study: a substudy of ACTFAST. *Kidney International* 2008;74:S60-S63.
9. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Gensini G, Leiter LA, Langer A, Martineau P, Hernandez G, Egido J, on behalf of the ACTFAST Investigators. Increased soluble FAS plasma levels in subjects at high cardiovascular risk. Atorvastatin on inflammatory markers (AIM) study, a sub-study of ACTFAST. *Arterioscler Thromb Vasc Biol* 2007;27:168-174.
10. Martineau P, Gaw A, de Teresa E, Farsang C, Gensini GF, Leiter LA, Langer A, on behalf of the ACTFAST Investigators. Effect of individualizing starting doses of a statin according to baseline LDL-cholesterol levels on achieving cholesterol targets: The achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study. *Atherosclerosis* 2007;191:135-146.
11. Blanco-Colio LM, Martin-Ventura JL, de Teresa E, Farsang C, Gaw A, Path MRC, Gensini GF, Leiter LA, Langer A, Martineau P, Hernández G, Egido J, on behalf of the ACTFAST investigators. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: A sub-study of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration. *Am Heart J* 2007;153:881-888.

DRIVE Study

MANUSCRIPTS

1. Braga MFB, Casanova A, Teoh H, Gerstein HC, Fitchett DH, Honos G, McFarlane PA, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA, on behalf of the Diabetes Registry to Improve Vascular Events (DRIVE) Investigators. Poor achievement of guidelines-recommended targets in type 2 diabetes: Findings from a contemporary prospective cohort study. *Int J Clin Pract* 2012;66:457:464.
2. Braga MFB, Casanova A, Teoh H, Dawson KG, Gerstein HC, Fitchett DH, Harris SB, Honos G, McFarlane PA, Steele A, Ur E, Yale JF, Langer A, Goodman SG, Leiter LA, on behalf of the Diabetes Registry to Improve Vascular Events (DRIVE) Investigators. Treatment Gaps in the Management of Cardiovascular Risk Factors in Patients with Type 2 Diabetes in Canada. *Can J Cardiol* 2010;26:297-302.

DRIVE Study

ABSTRACT

1. Langer A, Goodman S, Dawson K, Fitchett D, Gerstein HC, Harris S, Honos G, McFarlane P, Steele A, Ur E, Yale JF, Leiter L. Ongoing Care Gap in Canadian Diabetes Management. *Can J Cardiol* 2006;22(Suppl D):83D.

DYSIS

MANUSCRIPT

1. Goodman SG, Langer A, Bastien NR, McPherson R, Francis GA, Genest Jr JJ, Leiter LA, on behalf of the DYSIS Canadian Investigators. Prevalence of dyslipidemia in statin-treated patients in Canada: Results of the DYSlipidemia International Study (DYSIS). *Can J Cardiol* 2010;26(9):e330-e335.

DYSIS

ABSTRACT

1. Leiter LA, Goodman SG, Langer A, Bastien N, McPherson R, Francis G, Genest J, on behalf of the DYSIS investigators. High prevalence of dyslipidemia in patients treated with statins in Canada: Results of the Dyslipidemia International Study. *Can J Cardiol* 2009;25(Suppl B):257B.

GOALL / VP

MANUSCRIPTS

1. Bhan V, Yan RT, Leiter LA, Fitchett DH, Langer A, Lonn E, Tan M, Silagy S, Goodman SG, Yan AT, Guidelines Oriented Approach in Lipid Lowering (GOALL) Registry and Vascular Protection (VP) Registry Investigators. Relation between obesity and the attainment of optimal blood pressure and lipid targets in high vascular risk outpatients. *Am J Cardiol* 2010;106:1270-1276.
2. Wijeyesundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O'Flaherty M, Krahn M, Capewell S. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994-2005. *JAMA* 2010;303:1841-47.
3. Saposnik G, Goodman SG, Leiter LA, Yan RT, Fitchett DH, Bayer NH, Casanova A, Langer A, Yan AT, for the Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators* and on behalf of the Stroke Outcome Research Canada (SORCan) Working Group. Applying the evidence: Do patients with stroke, coronary artery disease or both achieve similar treatment goals? *Stroke* 2009;40:1417-24.
4. Tsang JLY, Mendelsohn A, Tan MKK, Hackam DG, Leiter LA, Fitchett D, Lin PJ, Grima E, Langer A, Goodman SG, for the Vascular Protection Registry and Guidelines Oriented Approach to Lipid Lowering Registry Investigators. Discordance between Physicians' Estimation of Patient Cardiovascular Risk and Use of Evidence-Based Medical Therapy. *Am J Cardiol* 2008;102:1142-1145.
5. Grima DT, Leiter LA, Goodman SG, Attard CL, Chow CM, Langer A. How Many Cardiovascular Events Can Be Prevented With Optimal Management of High-Risk Canadians? *Can J Cardiol* 2008;24(5):363-68.
6. Hackam DG, Leiter LA, Yan AT, Yan RT, Mendelsohn A, Tan M, Zavodni L, Chen R, Tsang JL, Kunki A, Lin PJ, Fitchett DH, Langer A, Goodman SG, for the Vascular Protection Registry and Guidelines Oriented Approach to Lipid Lowering Registry Investigators. Missed opportunities for the secondary prevention of cardiovascular disease in Canada. *Can J Cardiol* 2007;23:1124-1130.
7. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, Tsang JL, Jaffer S, Kates ML, Leiter LA, Fitchett DH, Langer A, Goodman SG, for the Vascular Protection (VP) and Guidelines Oriented Approach to Lipid Lowering (GOALL) Registries Investigators. Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met. *Am J Med* 2006 Aug;119(8):676-83.
8. Hackam DG, Tan MK, Lin PJ, Mehta PG, Jaffer S, Kates ML, Oh M, Grima EA, Langer A, Goodman SG. Vascular Protection Registry and Guideline Oriented Approach in Lipid Lowering Registry Investigators. Supporting a call to action for peripheral vascular disease: Insights from two prospective registries. *J Vasc Surg* 2006;44:776-81.
9. Hackam DB, Tan MKK, Honos GN, Leiter LA, Langer A, Goodman SG, for the Vascular Protection (VP) Registry Investigators. How does the prognosis of diabetes compare with that of established vascular disease? Insights from the Canadian Vascular Protection (VP) Registry. *Am Heart J* 2004;148:1028-33.

GOALL / VP

ABSTRACTS

1. Elbarasi E, Goodman SG, Yan RT, Casanova A, Tan M, Hackam DG, Leiter LA, Langer A, Yan AT. Management of risk factors among ambulatory patients at high cardiovascular risk in Canada: Can we do better? *Can J Cardiol* 2010;26(Suppl D):89D.
2. Bhan V, Goodman SG, Yan RT, Leiter LA, Fitchett D, Langer A, Lonn EM, Tan M, Silagy S, Yan AT. Obesity is associated with failure to attain optimal blood pressure and lipid targets in high vascular risk outpatients in Canada. *Can J Cardiol* 2009; 25(Suppl B):95B.
3. Wijeyesundera HC, Marchado M, Witteman W, Farahati F, van der Velde G, Tu JV, Lee DS, Goodman SG, Petrella R, O'Flaherty M, Krahn M, Capewell S. Reductions in coronary heart disease mortality associated with changes in risk factors in Ontario between 1994 and 2005. *Can J Cardiol* 2009;25(Suppl B):97B.
4. Yan AT, Yan RT, Saposnik G, Fitchett DH, Leiter L, Langer A, Goodman SG. Treatment of Dyslipidemia in Patients with Cerebrovascular Disease: the Canadian VP and GOALL Registries Experience. *J Am Coll Cardiol* 2008;51(Suppl A):A238.
5. Saposnik G, Yan AT, Casanova A, Langer A, Goodman SG, for the Stroke Outcome Research Canada (SORCan) Working Group. Gender Differences In The Management Of Cerebrovascular Disease: The Challenge Of Secondary Prevention. *Stroke* 2008;39(2):555.
6. Saposnik G, Yan AT, Yan RT, Fitchett D, Neville Bayer N, Leiter L, Langer A, Goodman SG, for the Guidelines Oriented Approach in Lipid Lowering (GOALL) Registry and Vascular Protection (VP) Registry. Differences In Target Achievement Among Patients With Cardiovascular, Stroke Or Combined Disease *Stroke* 2008;39(2):622.
7. Yan RT, Yan AT, Saposnik G, Fitchett DH, Leiter L, Langer A, Goodman SG. Treatment of Dyslipidemia in Patients with Cerebrovascular Disease: the Canadian VP and GOALL Registries Experience. *Can J Cardiol* 2007;23(Suppl C):99C.
8. Langer A, Grima DT, Leiter LA, Attard CL, Goodman SG. The Real Cost of Care Gap in Management High Cardiovascular Risk Patients: A Canadian Population Analysis. *Can J Cardiol* 2006;22(Suppl D):111D.
9. Yan RT, Yan AT, Tan M, Leiter LA, Fitchett D, Langer A, Goodman SG. High Vascular Risk Patients and Achievement of Guideline-Recommended LDL-Cholesterol Targets: Predictors of Treatment Failure. *Can J Cardiol* 2006; 22(Suppl D):84D.
10. Tsang JLY, Mendelsohn A, Tan M, Hackam DG, Leiter L, Fitchett D, Langer A, Goodman SG for the VP & GOALL Registry Investigators. The Use of Evidence-Based Cardioprotective Medications in High Vascular Risk Canadian Outpatients is Suboptimal. *Circulation* 2005;112(Suppl):II-445.
11. Yan RT, Yan AT, Tan M, Kertland HR, Leblanc KL, Leiter LA, Kates ML, Leong JC, Fitchett DH, Langer A, Goodman SG. Age-related Differences in the Lipid Profile and Use of Statin Therapy Among High Risk Patients: Targets Still Not Being Met. *Can J Cardiol* 2005;21(Suppl C):54C.
12. Yan AT, Yan RT, Tan M, Oh M, Kertland HR, Leblanc KL, Leiter LA, Chan J, Zavodni L, Langer A, Goodman SG, for the GOALL Registry Investigators. Canadian Patients at High Vascular Risk Received Suboptimal Doses of Statin Therapy With Only Half Achieving Guideline-Recommended Lipid Targets. *Can J Cardiol* 2005;20(Suppl D):181D.
13. Yan AT, Yan RT, Tan M, Oh M, Lonn E, Hackam DG, Chen RY, Booth G, Leiter LA, Langer A, Goodman SG, for the GOALL Registry investigators. Diabetic Patients Were Less Likely to be Treated with Guideline-Recommended Therapies, *Can J Cardiol* 2004;20(Suppl D):181D.
14. Yan RT, Yan AT, Tan M, Oh M, Leiter LA, Lonn E, Cheng AY, Langer A, Goodman SG, for the GOALL Registry Investigators. Obesity is an Independent Predictor and Therapeutic Target of Metabolic Abnormalities Among Treated High Vascular Risk Canadian Patients. *Can J Cardiol* 2004;20(Suppl D):183D.

GUIDE / GUIDANC Registries

MANUSCRIPTS

1. Katz PM, Mendelsohn AA, Goodman SG, Langer A, Teoh H, Leiter LA. Use of a treatment optimization algorithm involving statin-ezetimibe combination aids in achievement of guideline-based low-density lipoprotein targets in patients with dyslipidemia at high vascular risk. Guideline-based Undertaking to Improve Dyslipidemia mANagement in Canada (GUIDANC). Can J Cardiol 2011;27:138-45.
2. Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RYY, Tija S, Theriault L, Langer A, Leiter LA, on behalf of the Guidelines based Undertaking for Improvement in Dyslipidemia related Events (GUIDE) Investigators. Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease. Am J Cardiol 2009;104:798-804.

GUIDE / GUIDANC Registries

ABSTRACT

1. Langer A, Bissonnette S, Goodman SG, Tan M, Casanova A, Leiter LA. Dyslipidemia Management in Patients with Diabetes: The Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Experience. Can J Cardiol 2007;23(Suppl C):196C.

T2DM Registry

MANUSCRIPT

1. Teoh H, Braga MFB, Casanova A, Drouin D, Goodman SG, Harris SB, Langer A, Tan MK, Ur E, Yan AT, Zinman B, Leiter LA, on behalf of the T2DM Queri Investigators. Time 2 Do More Quality Enhancement Research Initiative (T2DM QUERI): Patient age, ethnicity, medical history and risk factor profile, but not drug insurance coverage, predict successful attainment of glycemic targets. *Diabetes Care* 2010;33(12):2558-2560.

T2DM Registry

ABSTRACTS

1. Teoh H, Braga MFB, Casanova A, Drouin D, Goodman SG, Harris SB, Langer A, Tan M, Ur E, Woo V, Zinman B, Leiter LA. Time 2 Do More: Feedback based national glycemic treatment optimization program can improve attainment of glycemic targets. *Can J Diabetes* 2009;33(3):198.
2. Teoh H, Braga MFB, Casanova A, Drouin D, Goodman SG, Harris SB, Langer A, Tan M, Ur E, Woo V, Zinman B, Leiter LA. Private drug coverage is not associated with better attainment of glycemic targets in a Canadian glycemic treatment optimization program. *Can J Diabetes* 2009;33(3):266.
3. Braga MFB, Teoh H, Tan M, Casanova A, Dawson K, Drouin D, Harris SB, Ur E, Woo V, Yale JF, Zinman B, Goodman SG, Langer A, Leiter LA. Impact of a Treatment Care Optimization Approach on the Management of Cardiovascular Risk Factors in Canadian Patients with Type 2 Diabetes Mellitus. *Can J Cardiol* 2009;25(Suppl B):219B.

IV ECG CORE LABORATORY

ECG Core Laboratory

MANUSCRIPTS

1. Ali S, Goodman SG, Yan RT, Budaj A, Fox KAA, Gore JM, Brieger D, López-Sendón J, Langer A, van de Werf F, Steg G, Yan AT. Prognostic significance of electrocardiographic-determined left ventricular hypertrophy and associated ST-segment depression in patients with non-ST-elevation acute coronary syndromes. *Am Heart J* 2011;161:878-85.
2. Baslaib F, Alkaabi S, Yan AT, Yan RT, Dorian P, Nanthakumar K, Casanova A, Goodman SG. QRS Prolongation in Patients with Acute Coronary Syndromes. *Am Heart J* 2010;159:593-8.
3. Johanson P, Fu Y, Wagner GS, Goodman SG, Granger CB, Wallentin L, Van de Werf F, Armstrong PW; ASSENT 3 Investigators. ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3. *Am J Cardiol* 2009;103(2):154-8.
4. Baine KR, Fu Y, Wagner GS, Goodman SG, Ross A, Granger CB, Van de Werf F, Armstrong PW; ASSENT 4 PCI Investigators. Spontaneous reperfusion in ST-elevation myocardial infarction: comparison of angiographic and electrocardiographic assessments. *Am Heart J* 2008;156:248-55.
5. McDonald MA, Fu Y, Zeymer U, Wagner GS, Goodman SG, Ross AM, Granger CB, Van de Werf F, Armstrong PW, for the ASSENT-4 PCI Investigators. Adverse outcomes in fibrinolytic-based facilitated percutaneous coronary intervention: Insights from the ASSENT-4 PCI Electrocardiographic Substudy. *Eur Heart J* 2008;29:871-9.
6. Yan RT, Yan AT, Granger CB, Lopez-Sendon J, Brieger D, Kennelly B, Budaj A, Steg PG, Georgescu AA, Hassan Q, MD, Goodman SG, on behalf of the Global Registry of Acute Coronary Events (GRACE) Electrocardiogram Substudy Group. Usefulness of Quantitative Versus Qualitative ST-Segment Depression for Risk Stratification of Non-ST Elevation Acute Coronary Syndromes in Contemporary Clinical Practice. *Am J Cardiol* 2008;101:919-924.
7. Vijayaraghavan R, Yan AT, Tan M, Fitchett DH, Georgescu AA, Hassan Q, Langer A, Goodman SG, for the Canadian Acute Coronary Syndromes Registry Investigators. Local Hospital vs. Core-Laboratory Interpretation of the Admission Electrocardiogram in Acute Coronary Syndromes: Increased Mortality in Patients with Unrecognized ST-Elevation Myocardial Infarction. *Eur Heart J* 2008;29:31-7.
8. Toma M, Fu Y, Wagner GS, Goodman SG, Granger CB, Wallentin L, Van de Werf F, Armstrong PW. Risk stratification in ST elevation myocardial infarction is enhanced by combining baseline ST deviation and subsequent ST segment resolution. *Heart* 2008; 94:e6.
9. Yan RT, Yan AT, Allegrone J, Lopez-Sendon J, Granger CB, Gore JM, Budaj A, Georgescu AA, Hassan Q, Luchansky J, Van de Werf F, Goodman SG. Differences Between Local Hospital and Core Laboratory Interpretation of the Admission Electrocardiogram in Patients With Acute Coronary Syndromes are Associated with Worse Outcome. *Am J Cardiol* 2007; 100:169-174.
10. Goodman SG, Fu Y, Langer A, Barr A, Tan M, Wagner GS, Barbagelata A, Sgarbossa EB, Birnbaum Y, Granger CB, Califf RM, Van de Werf F, Topol EJ, Armstrong PW, for the GUSTO-IIb Investigators. The prognostic value of the admission and pre-discharge electrocardiogram in acute coronary syndromes: the GUSTO-IIb ECG Core Laboratory experience. *Am Heart J* 2006;152(2):277-84.
11. Yan AT, Yan RT, Tan M, Chow CM, Fitchett DH, Georgescu A, Hassan Q, Luchansky J, Langer A, Goodman SG. ST-segment depression in non-ST elevation acute coronary syndromes: Quantitative analysis may not provide incremental prognostic value beyond comprehensive risk stratification. *Am Heart J* 2006;152(2):270-76.
12. Al-Faleh H, Fu Y, Wagner G, Goodman S, Sgarbossa E, Granger C, Van de Werf F, Wallentin L, Armstrong PW. Unraveling the spectrum of left bundle branch block in acute myocardial infarction: Insights from the Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT 2 and 3) trials. *Am Heart J* 2006;151:10-15.

13. Petrina M, Goodman SG, Eagle K. The Twelve-Lead Electrocardiogram as a Predictive Tool of Mortality after Acute Myocardial Infarction – Current Status in an Era of Revascularization and Reperfusion. *Am Heart J* 2006;152(1):11-8.
14. Goodman SG, Bozovich GE, Tan M, Dos Santos A, Gurfinkel EP, Cohen M, Langer A, for the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group (ESSENCE) Study Group. The greatest benefit of enoxaparin over unfractionated heparin in acute coronary syndromes is achieved in patients presenting with ST segment changes: The ESSENCE ECG Core Laboratory Substudy. *Am Heart J* 2006;151:791-797.
15. Georgescu A, Fu Y, Yau C, Hassan Q, Luchansky J, Armstrong PW, Wagner G, Van de Werf F, Goodman SG, for the Assessment of the Safety and Efficacy of a new Thrombolytic Regimen Trial (ASSENT-3) Investigators. Short and Long Term Outcomes of Patients with Electrocardiographic Left Ventricular Hypertrophy After Fibrinolysis for Acute Myocardial Infarction. *Am J Cardiol* 2005;92:1050-1052.
16. Johanson P, Armstrong PW, Barbagelata NA, Chaitman BR, Clemmensen P, Dellborg M, French J, Goodman SG, Green CL, Krucoff MW, Langer A, Pahlm O, Reilly P, Wagner GS. An academic ECG Core Lab perspective of the FDA initiative for digital ECG capture and data management in large-scale clinical trials. *Drug Information Journal* 2005;39:345-351.
17. Alexander JH, Yang H, Becker RC, Kodama K, Goodman S, Dyke CK, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff AM, Burton JR, Bovill EG, Kawai C, Armstrong PW, Harrington RA, on behalf of the XaNADU-ACS Investigators. First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: Results of the XaNADU-ACS Trial. *Journal of Thrombosis Haemostasis* 2005;3:439-447.
18. Taher T, Fu Y, Wagner GS, Goodman SG, Fresco C, Granger CB, Wallentin L, Van de Werf F, Verheugt F, Armstrong PW. Aborted Myocardial Infarction in Patients With ST-Segment Elevation Insights From the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen-3 Trial Electrocardiographic Substudy. *J Am Coll Cardiol* 2004;44:38-43.
19. Johanson P, Fu Y, Goodman SG, Dellborg M, Armstrong PW, Krucoff MW, Wallentin L, Wagner GS. A dynamic model forecasting myocardial infarct size before, during and after reperfusion therapy – An ASSENT-2 ECG/VCG substudy. *Eur Heart J* 2005;26:1726-33.
20. Barbagelata A, Di Carli MF, Califf RM, Garg J, Birnbaum Y, Grinfield L, Gibbons RJ, Granger CB, Goodman SG, Wagner GS, Mahaffey KW. Electrocardiographic infarct size assessment after thrombolysis: Insights from the acute myocardial infarction Study Adenosine (AMISTAD) trial. *Am Heart J* 2005;150:659-665.
21. Kaul P, Newby LK, Fu Y, Mark DB, Goodman SG, Wagner GS, Harrington RA, Granger CB, Van de Werf F, Ohman EM, Armstrong PW, for the VIGOUR Group. The Relationship between Baseline Risk and Treatment Decisions in Non-ST Elevation Acute Coronary Syndromes: An Examination of International Practice Patterns. *Heart* 2005;91:876-881
22. Armstrong PW, Wagner B, Goodman SG, Van de Werf F, Granger G, Wallentin L, Fu Y, for the ASSENT 3 Investigators. ST segment resolution in ASSENT 3: insights into the role of three different treatment strategies for acute myocardial infarction. *Eur Heart J* 2003;24:1515-22
23. Lockwood E, Fu Y, Wing B, Van de Werf F, Granger CB, Armstrong PW, Goodman SG for the ASSENT-2 Investigators. Does 24-hour ST-segment resolution postfibrinolysis add prognostic value to a Q wave? An ASSENT 2 electrocardiographic substudy. *Am Heart J* 2003;146:640-5.

ECG Core Laboratory

MANUSCRIPTS - CONTINUED

24. Tjandrawidjaja MC, Fu Y, Goodman SG, Van de Werf F, Granger CB, Armstrong PW. The impact of gender on the treatment and outcomes of patients with early reinfarction after fibrinolysis: Insights from ASSENT 2. *Eur Heart J* 2003;24:1024-34.
25. Goodman SG, Barr A, Langer A, Wagner GS, Fitchett D, Armstrong PW, Naylor CD. Development and prognosis of non-Q wave myocardial infarction in the thrombolytic era. *Am Heart J* 2002;144:243-50.
26. Fu Y, Goodman S, Chang W-C, Van de Werf F, Granger CB, Armstrong PW, for the ASSENT-2 Investigators. Time to treatment influences the impact of ST segment resolution on one-year prognosis: insights from ASSENT 2. *Circulation* 2002;104:2653-59.
27. Kaul P, Fu Y, Chang WC, Harrington RA, Wagner GS, Goodman SG, Granger CB, Moliterno DJ, Van de Werf F, Califf RM, Topol EJ, Armstrong PW, for the PARAGON-A and GUSTO-IIb Investigators. Prognostic value of ST segment depression in acute coronary syndromes: insights from PARAGON-A applied to GUSTO-IIb. *J Am Coll Cardiol* 2001;38:64-71.
28. Birnbaum Y, Goodman S, Barr A, Gates KB, Barbash GI, Battler A, Barbagelata A, Clemmensen P, Sgarbossa EB, Granger CG, Califf RM, Wagner GS. Comparison of primary coronary angioplasty versus thrombolysis in patients with ST-segment elevation acute myocardial infarction and grade II and grade III myocardial ischemia on the enrollment electrocardiogram. *Am J Cardiol* 2001;88:842-847.
29. Anderson S, Pahlm O, Bacharova L, Barbagelata A, Chaitman B, Clemmensen P, Goodman S, Heden B, Klootwijk P, Lauer M, MacFarlane P, Rautaharju P, Reddy S, Selvester R, Sgarbossa E, Underwood D, Warner R, Wagner G. Standards for the function of an academic 12-lead electrocardiographic core laboratory. *J Electrocardiol* 2001;34:41-47.
30. Barbash GI, Birnbaum Y, Bogaerts K, Hudson M, Lesaffre E, Fu Y, Goodman SG, Houbracken K, Munsters K, Granger CB, Pieper K, Califf RM, Topol EJ, van de Werf F. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction: an analysis of outcome and treatment choices in the GUSTO I and ASSENT 2 studies. *Circulation* 2001;103:954-960.
31. Sgarbossa EB, Meyer PM, Pinski SL, Pavlovic-Surjancev B, Barbagelata A, Goodman SG, Lum AS, Underwood DA, Gates KB, Califf RM, Topol EJ, Wagner GS. Negative T waves shortly after ST-elevation acute myocardial infarction are a powerful marker for improved survival rate. *Am Heart J* 2000;140:385-94.
32. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Knight D, Mark DB, Granger CB, Ohman M, Wagner G. The use of resources, quality of life and clinical outcomes in patients with and without new Q waves after thrombolytic therapy for acute myocardial infarction (from GUSTO-I). *Am J Cardiol* 2000;86:24-29.
33. Sgarbossa EB, Pinsky SL, Barbagelata A, Goodman SG, Natale A, Gates KB, Wagner GS. ECG subanalyses in clinical trials: an investigator's perspective. *J Electrocardiol* 1999;32(suppl):114-121.
34. Hochrein J, Fucheng S, Pieper KS, Lee KL, Gates K, Armstrong PW, Weaver WD, Goodman S, Topol EJ, Califf RM, Granger CB, Wagner GS. Higher T-wave amplitude associated with better prognosis in patients receiving thrombolytic therapy for acute myocardial infarction (a GUSTO-I substudy). *Am J Cardiol* 1998;81:1078-1084.
35. Goodman S, Langer A, Ross AM, Wildermann NM, Barbagelata A, Sgarbossa EG, Wagner GS, Granger CB, Califf RM, Topol EJ, Simoons ML, Armstrong PW, for the GUSTO-I Angiographic Investigators. Non-Q versus Q-wave myocardial infarction after thrombolytic therapy: angiographic and prognostic insights from the GUSTO-I angiographic substudy. *Circulation* 1998;97:444-450.
36. Sgarbossa EB, Pinski SL, Topol EJ, Califf RM, Barbagelata A, Goodman SG, Gates KB, Granger CB, Miller DP, Underwood DA, Wagner GS, for the GUSTO-I Investigators. Acute myocardial infarction and complete left bundle branch block at hospital admission: clinical characteristics and outcome in the thrombolytic era. *J Am Coll Cardiol* 1998;31:105-110.

37. Barbagelata A, Califf RM, Sgarbossa EB, Goodman SG, Stebbins AL, Granger CB, Suarez LD, Borruel M, Gates K, Starr S, Wagner GS. Thrombolysis and Q wave versus non-Q wave first acute myocardial infarction: a GUSTO-I substudy. *J Am Coll Cardiol* 1997;29:770-777.
38. Langer A, Goodman SG, Topol EJ, Charlesworth A, Skene AM, Wilcox RG, Armstrong PW for the LATE Study Investigators. Late assessment of thrombolytic efficacy (LATE) study: Prognosis in patients with non-Q wave myocardial infarction. *J Am Coll Cardiol* 1996;27:1327-1332.
39. Singh N, Mironov D, Goodman SG, Morgan CD, Langer A. Treatment of silent ischemia in unstable angina: a randomized comparison of sustained-release verapamil versus metoprolol. *Clin Cardiol* 1995;18:653-658.

ECG Core Laboratory

ABSTRACTS

1. Elbarouni B, Hutchinson-Jaffe AB, Goodman SG, Yan RT, Baer C, Lai C, Eagle KA, Langer A, Rose BF, Wald R, Yan AT. Differences in the baseline characteristics and management of non-ST segment elevation myocardial infarction patients as a function of participation in clinical trials. *Can J Cardiol* 2010;26(Suppl D):31D.
2. Ali S, Goodman SG, Yan RT, Brieger D, Budaj A, Lopez-Sendon J, Fox FAA, Gore JM, Langer A, Steg PG, Van de Werf F, Yan AT. Prognostic significance of electrocardiographic left ventricular hypertrophy and associated ST-segment depression in non-ST elevation acute coronary syndromes. *Can J. Cardiol* 2010;26(Suppl D):111D.
3. Rousseau M, Yan RT, Goodman SG, Lefkowitz CJ, Casanova A, Fitchett DH, Jolly SS, Langer A, Tan M, Yan AT. The relationship between hemoglobin level and recurrent ischemia in acute coronary syndromes: Insights from continuous ECG monitoring. *Can J Cardiol* 2010;26(Suppl D):111D.
4. McDonald MA, Fu Y, Zeymer U, Wagner GS, Goodman SG, Ross AM, Granger CB, Van de Werf F, Armstrong PW. Adverse Outcomes in Fibrinolytic-Based Facilitated PCI: Insights From the ASSENT-4 PCI electrocardiographic Substudy. *Can J Cardiol* 2007;23(Suppl C):223C.
5. McDonald MA, Fu Y, Zeymer U, Wagner GS, Goodman SG, Ross AM, Granger CB, Van de Werf F, Armstrong PW. Adverse Outcomes in Fibrinolytic-Based Facilitated PCI: Insights From the ASSENT-4 PCI electrocardiographic Substudy. *Eur Heart J* 2007;28(Suppl 1):59.
6. Petrina M, Eagle KA, Lopez-Sendon J, Step PG, Fox KA, Stiles M, Quill A, Goodman SG, for the GRACE Investigators. The Prognostic Value of the 12-Lead Electrocardiogram (ECG) in Patients Presenting with Acute Coronary Syndromes (ACS): Insights from the Global Registry of Acute Coronary Events (GRACE) ECG Substudy. *J Am Coll Cardiol* 2007;49(Suppl A):187A.
7. Yan AT, Yan RT, Allegrone J, Kennelly B, Anderson F, Steg PG, Goodman SG. Prevalence and Prognostic Significance of ST Elevation In aVR in Patients with Non-ST Elevation Acute Coronary Syndromes. *Can J Cardiol* 2006; 22(Suppl D):193D.
8. Yan RT, Yan AT, Allegrone J, Lopez-Sendon J, Granger C, Gore J, Budaj A, Georgescu A, Hassan Q, Goodman SG. Failure To Identify ST-Segment Deviation Or Left Bundle Branch Block On The Presenting Electrocardiograms In Patients With Acute Coronary Syndromes Is Related To More Adverse Clinical Outcome. *Can J Cardiol* 2006; 22(Suppl D):194D.

ECG Core Laboratory

ABSTRACTS - CONTINUED

9. Yan RT, Yan AT, Allegrone J, Kennelly B, Budaj A, Georgescu A, Hassan Q, Goodman SG. ST-segment Depression in Non-ST Elevation Acute Coronary Syndromes: Quantitative Analysis Does Not Provide Incremental Prognostic Value Beyond Comprehensive Risk Stratification. *Can J Cardiol* 2006; 22(Suppl D):190D.
10. Yan AT, Yan RT, Tan M, Mendelsohn A, Jolly S, Fitchett D, Langer A, Goodman SG. Global Registry of Acute Coronary Events (GRACE) Risk Score and Continuous ST-Segment Monitoring Provide Complementary Long-Term Prognostic Information in Patients with Non-ST Elevation Acute Coronary Syndromes. *Can J Cardiol* 2006; 22(Suppl D):167D.
11. Fu Y, Goodman SG, Wagner G, Granger CB, Van de Werf F, Ross A, Armstrong PW. Q-Waves at Presentation Relate to Presentation Delay and Predict Reperfusion Likelihood and Subsequent Mortality. *Can J Cardiol* 2006;22(Suppl D):166D.
12. Baine KR, Fu Y, Wagner G, Goodman SG, Ross A, Granger CB, Van de Werf F, Armstrong PW. Early ST Resolution in STEMI: Spontaneous Reperfusion in Acute Myocardial Infarction. *Can J Cardiol* 2006;22(Suppl D):165D.
13. Westerhout CM, Chang WC, Fu Y, Goodman SG, Van de Werf F, Granger CB, Armstrong PW. Are STEMI outcomes after fibrinolysis worse during “off hours”? Insights on circadian rhythm from ASSENT-2. *Circulation* 2005; 112(Suppl):II-320.
14. Toma M, Fu Y, Wagner G, Goodman SG, Van de Werf F, Granger CB, Wallentin L, Armstrong PW, for the ASSENT 3 Investigators. Enriching The Prognostic Value Of The Baseline ECG In STEMI. *Can J Cardiol* 2005;21(Suppl C):247C.
15. Toma M, Fu Y, Wagner G, Goodman SG, Van de Werf F, Granger CB, Wallentin L, Armstrong PW, for the ASSENT 3 Investigators. Risk Stratification In STEMI Is Enhanced By Using Both Baseline ST Deviation And ST Resolution At 180 mins. *Can J Cardiol* 2005;21(Suppl C):163C.
16. Westerhout CM, Chang WC, Fu Y, Goodman SG, Van de Werf F, Granger CB, Armstrong PW. Are STEMI Outcomes After Fibrinolysis Worse During “Off Hours”? Insights On Circadian Rhythm From ASSENT-2. *Can J Cardiol* 2005;21(Suppl C):90C.
17. Taher T, Al-Kurtass S, Fu Y, Wagner G, Goodman SG, Welsh R, Granger C, Wallentin L, Van de Werf F, Armstrong PW. The ECG Adds Value to Time to Treatment in Predicting Aborted Myocardial Infarction. *JACC* 2005;45(Suppl A):194A.
18. Yan AT, Goodman SG, Kennelly BM, Anderson FA, Allegrone J, Steg PG, on behalf of the GRACE Investigators. Prevalence and prognostic significance of ST elevation in aVR: Insights from the Global Registry of Acute Coronary Events Electrocardiographic Substudy. *Eur Heart J* 2005;26 (Abstr Suppl):282.
19. Alghamdi S, Fu Y, Goodman SG, Chang W-C, Van de Werf F, Granger CB, Armstrong PW. The Baseline ECG in ST Elevation Myocardial Infarction Provides Powerful Prognostic Insight: Observations from ASSENT 2. *J Am Coll Cardiol* 2005;45(Suppl A):208A.
20. Al-Kurtass S, Fu Y, Wagner G, Goodman S, Granger CB, Wallentin L, Van de Werf F, Armstrong PW. Does The Baseline ECG Add Value To Time To Treatment In Predicting Successful Reperfusion After Fibrinolysis?: Insight From ASSENT-3 And ASSENT 3+. *Can J Cardiol* 2004;20(Suppl D):108D.
21. Alexander J, Yang H, Becker RC, Kodama K, Dyke CK, Goodman SG, Kleiman NS, Hochman JS, Berger PB, Cohen EA, Lincoff M, Bovill EG, Kawai C, Armstrong PW, Harrington RA. Direct, selective factor Xa inhibition in patients with Non-ST elevation acute coronary syndromes from the United States, Canada, and Japan: results of the XaNADU-ACS Trial. *J Am Coll Cardiol* 2004;43(5;Suppl A):302A.
22. Yan AT, Yan R, Tan M, Fitchett DH, Cohen M, Armstrong PW, Langer A, Goodman SG. Early continuous ST monitoring identifies acute coronary syndrome patients at high risk of death and myocardial infarction despite contemporary treatment. *J Am Coll Cardiol* 2004;43(5;Suppl A):277A.
23. de Villiers JF, Fu Y, Wagner G, Goodman SG, Granger C, Wallentin L, Van de Werf F, Armstrong PW, for the ASSENT 3 Investigators. The acuteness score: new insights in predicting infarct size. *J Am Coll Cardiol* 2004;43(5;Suppl A):288A.

24. Johanson P, Fu Y, Dellborg M, Goodman SG, Armstrong PW, Krucoff MW, Wallentin L, Wagner GS. The model for a continuously updated weather-forecast before, during and after reperfusion therapy for estimations of final myocardial salvage: an ASSENT-2 electrocardiogram/VCG substudy. *Eur Heart J* 2003;24 Abstr Suppl:722.
25. Taher T, Fu Y, Wagner G, Goodman SG, Fresco C, Granger CB, Wallentin L, Van de Werf F, Armstrong PW, for the ASSENT 3 Investigators. Evidence for early reperfusion and preservation of myocardium: a new salvage subset. *J Am Coll Cardiol* 2003;41(suppl A):358A
26. Al Faleh H, Fu Y, Wagner GS, Goodman SG, Sgarbossa E, Granger CB, Van der Werf F, Wallentin L, Armstrong PW, for the ASSENT 3 Investigators. Unraveling the spectrum of LBBB in AMI: Insights from ASSENT 3. *J Am Coll Cardiol* 2003;41(suppl A):366A.
27. Leung R, Fu Y, Goodman SG, Wagner G, Granger CB, Wallentin L, Van de Werf F, Armstrong PW, for the ASSENT 3 investigators. Does open-label reperfusion therapy in ST-elevation acute myocardial infarction influence the frequency of urgent percutaneous coronary intervention? *Can J Cardiol* 2002;18(suppl B):140B.
28. Taher T, Fu Y, Wagner G, Goodman SG, Fresco C, Granger CB, Wallentin L, Van de Werf F, Armstrong PW for the ASSENT 3 Investigators. Evidence for early reperfusion and preservation of myocardium: the ECG characteristics of aborted MI. *Can J Cardiol* 2002;18(suppl B):241B.
29. Wagner G, Fu Y, Goodman SG, Granger CB, Wallentin L, Van de Werf F, Armstrong P, on behalf of the ASSENT III investigators. How does ST-segment resolution one-hour after fibrinolysis for acute myocardial infarction predict final infarct size? Insights from ASSENT 3. *Eur Heart J* 2002;23(Abstr Suppl):266.
30. Armstrong PW, Wagner GS, Goodman S, Van de Werf F, Granger CB, Fu Y. Impact of fibrinolytic regimens and elapsed time on resolution of ST elevation in acute MI: insights from the ASSENT 3 ECG substudy. *J Am Coll Cardiol* 2002;39(suppl B):95B.
31. Lockwood E, Fu Y, Wong B, Goodman S, Van de Werf F, Granger C, Armstrong PW, for the ASSENT-2 Investigators. Does 24-hour ST segment resolution post-fibrinolysis add prognostic value to a Q-wave? ASSENT-2 electrocardiographic sub-study. *Can J Cardiol* 2001;17(suppl C):182C-183C.
32. Fu Y, Goodman S, Van de Werf F, Granger C, Armstrong P. The nature and outcome of patients who avoid myocardial necrosis after fibrinolysis. *Eur Heart J* 2001;22(Suppl):179.
33. Fu Y, Goodman S, Chang W-C, Kaul P, Van de Werf F, Granger CB, Armstrong PW, for the ASSENT 2 Investigators. Time to treatment influences the impact of ST segment resolution on one year prognosis: insights from ASSENT-2. *J Am Coll Cardiol* 2001;37(suppl A):340A.
34. Fu Y, Goodman S, Chang W-C, Barr A, Lagos M, Jagasia P, Van de Werf F, Granger C, Armstrong PW, for the ASSENT II Investigators. Incidence and prognosis of non-Q wave MI in the thrombolytic era: insights from ASSENT II. *J Am Coll Cardiol* 2000;35(suppl.A):390A.
35. Sgarbossa EB, Pinsky SL, Pavlovic-Surjancev B, Barbagelata A, Goodman SG, Underwood DA, Lum AS, Palvas B, Allen JE, Starr S, Paredes A, Wagner GS. A new hierarchy for ECG stratification of acute myocardial infarction based in T wave polarity. *Circulation* 1998;98(suppl.I):I-555.
36. Sgarbossa EB, Pinski SL, Underwood DA, Stein S, Gates KB, Goodman S, Wager GS. Post-thrombolysis reversion of bundle branch block in acute myocardial infarction is associated with improved prognosis. *Electrocardiology* 1996;29:545-546.
37. Pinski SL, Steinberg JS, Goodman SG, Helguera ME, Connors S, Song Q, Lawson WT, Gates K, Wagner GS. Lack of agreement in QT dispersion measurement by 3 different methods. *PACE* 1996; 19(4, Part II): 667.
38. Goodman SG, Langer A, Wildermann N, Barbagelata A, Sgarbossa EB, Wagner GS, Granger CB, Ross AM, Armstrong PW, for the GUSTO Investigators. Non-Q wave vs. Q wave MI following thrombolysis: angiographic insights. *Circulation* 1995;92(suppl.):I-530.

ECG Core Laboratory

ABSTRACTS - CONTINUED

39. Goodman SG, Langer A, Wildermann N, Barbagelata A, Sgarbossa EB, Wagner GS, Granger CB, Califf RM, Ross AM, Armstrong PW, for the GUSTO Investigators. Non-Q wave vs. Q wave MI following thrombolysis: angiographic insights. *Can J Cardiol* 1995; 11 (suppl. E):110E.
40. Goodman SG, Langer A, Topol E, Armstrong PW. What is the natural history of non-Q infarction in the post thrombolytic era? *Can J Cardiol* 1993; 9(suppl.E):106E.
41. Goodman SG, Langer A, Freeman MR, Sutherland W, Armstrong PW. Ambulatory silent ischemia adds diagnostic value to exercise testing and thallium scintigraphy in stable angina. *Can J Cardiol* 1992; 8(suppl.B):81B.
42. Goodman SG, Langer A, Freeman MR, Sutherland W, Armstrong PW. Ambulatory silent ischemia adds diagnostic value to exercise testing and thallium scintigraphy in stable angina. *Circulation* 1992; 86(suppl. 4):I-185.
43. Goodman SG, Langer A, Sutherland W, Adams L, Armstrong PW. Does ambulatory silent myocardial ischemia identify patients with more significant coronary artery disease? *Can J Cardiol* 1991; 7(suppl. A):105A.

V CAN-REDUCE / DM-SCAN

CAN-REDUCE / DM-SCAN

MANUSCRIPTS

- 1 Teoh H, Després J-P, Dufour R, Fitchett DH, Goldin L, Goodman SG, Harris SB, Langer A, Lau DCW, Lonn EM, Mancini J, McFarlane PA, Poirier P, Rabasa-Lhoret R, Tan M, Leiter LA. Identification and management of patients at elevated cardiometabolic risk in Canadian primary care: How well are we doing? *Can J Cardiol* 2013;29:960-8.
- 2 Leiter LA, Berard L, Bowering CK, Cheng A, Dawson K, Ekoé J-M, Fournier C, Goldin L, Harris S, Lin P, Ransom T, Tan M, Teoh H, Tsuyuki R, Whitham D, Woo V, Yale J-F, Langer A. Type 2 diabetes mellitus management in Canada: Is it improving? *Can J Diabetes* 2013;37:82-9.
- 3 Teoh H, Després J-P, Dufour R, Fitchett DH, Goldin L, Goodman SG, Harris SB, Langer A, Lau DCW, Lonn EM, Mancini GBJ, McFarlane PA, Poirier P, Rabasa-Lhoret R, Tan MK, Leiter LA. A comparison of the assessment and management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care. *Diabetes, Obesity and Metabolism* 2013 (submitted).

CAN-REDUCE / DM-SCAN

ABSTRACTS

- 1 Teoh H, Després J-P, Fitchett DH, Galluzzi A, Goldin L, Goodman SG, Harris SB, Langer A, Lonn EM, Mancini GBJ, McFarlane PA, Poirier P, Rabasa-Lhoret R, Leiter LA. How do Canadian primary care physicians in family health teams compare with those in solo-physician practices in their assessment and management of patients with elevated cardiometabolic risk? *Can J Cardiol* 2012;28(5S):S183.
- 2 Teoh H, Després J-P, Fitchett DH, Galluzzi A, Goldin L, Goodman SG, Harris SB, Langer A, Lonn EM, Mancini GBJ, McFarlane PA, Poirier P, Rabasa-Lhoret R, Leiter LA. Are lifestyle modifications being appropriately recommended in the Canadian primary care practice to manage elevated cardiometabolic risk? *Can J Cardiol* 2012;28(5S):S387.
- 3 Teoh H, Després J-P, Fitchett DH, Galluzzi A, Goldin L, Goodman SG, Harris SB, Langer A, Lonn EM, Mancini GBJ, McFarlane PA, Poirier P, Rabasa-Lhoret R, Leiter LA. Underestimation of cardiovascular risk in patients with elevated cardiometabolic risk in the Canadian primary care setting. *Can J Cardiol* 2012;28(5S):S183.
- 4 Teoh H, Després J-P, Dufour R, Fitchett DH, Galluzzi A, Goldin L, Goodman SG, Harris SB, Langer A, Lau DCW, Lonn EM, Mancini GBJ, McFarlane PA, Poirier P, Rabasa-Lhoret R, Leiter LA. A comparison of how Canadian primary care physicians in family health teams and solo-physician practices manage cardiometabolic risk in patients with type 2 diabetes mellitus. *Can J Diabetes* 2012;36:S39-S40.
- 5 Teoh H, Després J-P, Dufour R, Fitchett DH, Galluzzi A, Goldin L, Goodman SG, Harris SB, Langer A, Lau DCW, Lonn EM, Mancini GBJ, McFarlane PA, Poirier P, Rabasa-Lhoret R, Leiter LA. Management of cardiometabolic risk in patients with and without type 2 diabetes mellitus in Canadian primary care settings. *Can J Diabetes* 2012;36:S12.

VI ATRIAL FIBRILLATION

Atrial Fibrillation

ABSTRACT

- 1 Goodman SG, Kerr CR, Green MS, Gladstone DJ, Mendelsohn A, Mitchell LB, Fournier C, Cox JL, Talajic M, Lin PJ, Langer A, Dorian P. The risk stratification and stroke prevention therapy care gap in Canadian atrial fibrillation patients: Insights from the Facilitating Review and Education to Optimize stroke prevention in Atrial Fibrillation (FREEDOM AF) knowledge translation program. *Can J Cardiol* 2011;27(5S):S121.

VII PULMONARY HYPERTENSION

Pulmonary Hypertension

MANUSCRIPTS

1. Khanna D, Tan M, Furst D, Hill N, McLaughlin V, Silver R, Steen V, Langer A, Seibold J. Recognition of pulmonary hypertension in the rheumatology community – Lessons from a quality enhancement research initiative. *Clin Exp Rheumatol* 2013 (in press).
2. McLaughlin VV, Langer A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, for the Pulmonary Arterial Hypertension – Quality Enhancement Research Initiative (PAH-QuERI) Investigators. Contemporary trends in the diagnosis and management of pulmonary arterial hypertension: An initiative to close the care gap. *CHEST* 2013;143(2):324-32.
3. Clements PJ, Tan M, McLaughlin VV, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ, Langer A, on behalf of the Pulmonary Arterial Hypertension Quality Enhancement Research Initiative (PAH-QuERI) Investigators. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH. *Ann Rheum Dis* 2012;71:249-52.

VIII MISCELLANEOUS STUDIES

Miscellaneous Studies

MANUSCRIPTS

1. Taljaard M, Ward MR, Kutryk MJB, Courtman DW, Camack NJ, Goodman SG, Parker TG, Dick AJ, Galipeau J, Stewart DJ. Rationale and Design of ENACT-AMI: The First Randomized Placebo-controlled Trial of Enhanced Progenitor Cell Therapy for Acute Myocardial Infarction. *Am Heart J* 2010;159:354-60.
2. Smyth SS, Woulfe DS, Weitz JI, Gachet C, Conley PB, Goodman SG, Roe MT, Kuliopulos A, Moliterno DJ, French PA, Becker RC, Steinhubl SR, for the 2008 Platelet Colloquium Participants. G-protein-coupled receptors as signaling targets for antiplatelet therapy. *Arterioscler Thromb Vasc Biol* 2009;29(4):449-57.
3. Goodman SG, Menon V, Cannon CP, Steg G, Ohman EM, Harrington RA. Acute ST-segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008;133:708S-775S.
4. Ko DT, Wijeyesundera HC, Zhu X, Richards J, Tu JV, and the CCORT/CCS/CAIC National Expert Panel: Carere RG, Cohen EA, Dzavik V, Fort S, Goodman SG, Knudtson ML, Love MP, Nallamothu BK, Rinfret S, Teo KK. Canadian Quality Indicators for Percutaneous Coronary Interventions. *Can J Cardiol* 2008;24:899-903.
5. Gibson M, Pride YB, Aylward PE, Col JJ, Goodman SG, Gulba D, Bergovec M, Kunadian V, Zorkun C, Buros JL, Murphy SA, Antman EM. Association of non-steroidal anti-inflammatory drugs with outcomes in patients with ST-segment elevation myocardial infarction treated with fibrinolytic therapy: an ExTRACT-TIMI 25 analysis. *J Thromb Thrombolysis* 2009;27:11-17.
6. Wiviott SD, Braunwald E, Angiolillo DJ, Meisel S, Dalby AJ, Verheugt FWA, Goodman SG, Corbalan R, Purdy A, Murphy SA, McCabe CH, Antman E, for the TRITON-TIMI 38 Investigators. Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy with Prasugrel in Patients with Diabetes Mellitus in TRITON - TIMI 38. *Circulation* 2008;118:1626-1636.
7. Cantor W, Kim H, Jolly S, Moe G, Mendelsohn A, Kleinfeld A, Fitchett D. B-Type Natriuretic Peptide and Serum Unbound Free Fatty Acid Levels after Contemporary Percutaneous Coronary Intervention. *J Invasive Cardiol* 2008;20:186-188.
8. Fitchett D, Goodman SG, Langer A. Ischemic Stroke: a Cardiovascular Risk Equivalent? Lesson Learned from the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. *Can J Cardiol* 2008;24(9):705-708.
9. Fitchett DH, Borgundvaag B, Cantor W, Cohen E, Dhingra S, Frenes S, Gupta M, Heffernan M, Kertland H, Husain M, Langer A, Letovsky E, Goodman SG, for the Renewal of Non STE ACS Algorithm Group. Non ST Segment Elevation Acute Coronary Syndromes: A Simplified Risk Oriented Algorithm. *Can J Cardiol* 2006;22:663-677.
10. Fitchett D, Leiter LA, Goodman SG, Langer A. Lower is better: Implications of the Treat to New Targets (TNT) Trial for Canadian Patients. *Can J Cardiol* 2006;22:835-839.
11. Kaul P, Newby LK, Fu Y, Mark DB, Goodman SG, Wagner GS, Harrington RA, Granger CB, Van de Werf F, Ohman EM, Armstrong, for the VIGOUR Group. Relation between baseline risk and treatment decisions in non-ST elevation acute coronary syndromes: an examination of international practice patterns. *Heart* 2005;91 876-881.
12. Fitchett DH, Leiter LA, Tardif JC, Goodman SG, Langer A. Are Canadian Guidelines for Cholesterol Lowering in High-Risk Patients Optimal ? *Can J Cardiol* 2005;21:85-90.
13. Fitchett D, Welsh R, Langer A, Goodman S. Enoxparin and percutaneous coronary intervention: a Canadian perspective. *Can J Cardiol* 2005;21(6):501-07.
14. Levine GN, Lincoff AM, Ferguson JJ, Mahaffey KW, Goodman SG, Cannon CP, Theroux P, Fox KAA. Utilization of catheterization and revascularization procedures in patients with non-ST segment elevation acute coronary syndrome over the last decade. *Catheterization and Cardiovascular Interventions* 2005;66:149-157.

Miscellaneous Studies

MANUSCRIPTS - CONTINUED

15. Hackam DG, Goodman SG, Anand SS. Management of risk in peripheral artery disease: Recent therapeutic advances. *Am Heart J* 2005;150:35-40.
16. Cantor WJ, Goodman SG, Cannon CP, Murphy SA, Charlesworth A, Braunwald E, Langer A. Early cardiac catheterization is associated with lower mortality only among high-risk patients with ST- and non-ST elevation acute coronary syndromes: Observations from the OPUS-TIMI 16 Trial. *Am Heart J* 2005;149:275-83.
17. Young W, McShane J, O'Connor T, Rewa G, Goodman SG, Jaglal SB, Cash L, Coyte PC, O'Connor T. Registered Nurses' experiences with an evidence-based home care pathway for myocardial infarction clients. *Canadian Journal of Cardiovascular Nursing* 2004;14:24-31.
18. Petersen JL, Mahaffey KW, Hasselblad V, Antman E, Cohen M, Goodman SG, Langer A, Blazing MA, Le-Moigne-Amrani A, DeLemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E; Califf RM. Efficacy and Bleeding Complications Among Patients Randomized to Enoxaparin or Unfractionated Heparin for Antithrombin Therapy in Non-ST-Segment Elevation Acute Coronary Syndromes: A Systematic Overview. *JAMA* 2004;292:89-96.
19. Sprecher DL, Goodman S, Kannampuzha P, Pearce GL, Langer A. Skin tissue cholesterol (SkinTc) is related to angiographically-defined cardiovascular disease. *Atherosclerosis* 2003;171:255-8.
20. Fitchett D, Goodman SG, Gupta M, Langer A. Preventing thrombosis: update of first-line therapy in the management of non ST segment elevation acute coronary syndromes. *Can J Cardiol* 2002;18:1179-1190.
21. Lee DS, Goodman S, Dean DM, Lenis J, Ma P, Gervais PB, Langer A. Randomized comparison of T-type versus L-type calcium-channel blockade on exercise duration in stable angina: results of the Posicor Reduction of Ischemia During Exercise (PRIDE) trial. *Am Heart J* 2002;144:60-7.
22. Fitchett D, Goodman SG, Langer A. New advances in the management of acute coronary syndromes: 1. Matching treatment to risk. *Can Med Assoc J* 2001;164(9):1309-16.
23. Fitchett D, Goodman SG, Langer A on behalf of The University of Toronto Div of Cardiology/Greater Toronto Area Community Cardiologists. Guidelines for the early management of acute coronary syndromes: focus on antithrombotic and antiplatelet therapy. *Can J Cardiol* 2000;16:1423-1432.
24. Barr A, Goodman S, Langer A. Bootstrap methods for selection of variables and for investigation of model stability, and the application of these methods to Cox proportional hazards. 14th International Workshop on Statistical Modelling; 1999:429-435.
25. Langer A, Fisher M, Califf RM, Goodman SG, O'Connor CM, Harrington RA, Fuster V, for the CARS Investigators. Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States as compared to Canada. *Can J Cardiol* 1999;15(10):1095-1102.
26. Langer A, Barr A, Goodman S, Stewart D. Canadian Acute Myocardial Infarction database: safety and potential benefit of heart rate lowering calcium channel blockers. *Drugs of Today* 1999; 35(suppl.B):17-19.
27. Goodman SG, Hill, C, Bata I, Fung A, Higginson, L, Lam J, Massel D, McCans J, Nasmith J, Stanton E, Thompson C, Warnica W, Langer A, for the the Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial (PROTECT) Study Research Group. Design of a randomized, double-blind clinical trial of diltiazem vs. atenolol in secondary prophylaxis post non-Q wave myocardial infarction. *Can J Cardiol*, 1996;12:1183-1190.
28. Goodman SG, Langer A, Durica SS, Raskob GE, Comp PC, Gary RJ, Hall JH, Kelley RP, Hua TA, Lee RJ, Fuster V. Safety and Anticoagulation Effect of a Low-Dose Combination of Warfarin and Aspirin in Clinically Stable Coronary Artery Disease. *Am J Cardiol* 1994;74:657-661.

Miscellaneous Studies

ABSTRACTS

1. McLaughlin VV, Langer A, Dragomir A, Casanova A, Tan M, Clements PJ, Oudiz RJ, Tapson VF, Channick RN, Rubin LJ. Contemporary trends in the diagnosis and management of PAH: An initiative to close the care gap. *CHEST* 2010;138(4):351A; *Circulation* 2010; 122:A11192.
2. Rizvi SJ, Casanova A, Tan M, Lin P, McIntyre RS, Grima E, Kennedy SH. The effect of depression in the workplace and contributing factors across Canada: Results from the InSight study. *The Canadian Journal of Psychiatry* 2010 (in press).
3. Rizvi SJ, Casanova A, Tan M, Lin P, McIntyre RS, Grima E, Kennedy SH. Treatment resistant depression in primary care and contributing factors across Canada: Results from the InSight study. *The Canadian Journal of Psychiatry* 2010 (in press).
4. Fitchett DH, Casanova A, Goodman SG, Tan M, Kornilova O, Langer A. Safety and efficacy of extended delayed release diltiazem for improved blood pressure control in family practice. *J Clin Hypertens* 2007;9(5)(Suppl A):A34.
5. Singh KP, Roe MT, Peterson ED, Chen AY, Mahaffey KW, Goodman SG, Harrington RA, Ohman EM, Gibler B, Pollack CV. The safety of anti-thrombin therapy in non-ST-segment elevation acute coronary syndrome patients. Results from the CRUSADE initiative. *J Am Coll Cardiol* 2005;45(Suppl A):233A.
6. Goodman SG, Barr A, Granger C, Ohman M, Langer A, Armstrong P, Gibler B, Topol E. Secular trends in the management of acute myocardial infarction medication errors and outcomes with fixed double-bolus r-PA vs bolus + weight-adjusted infusion t-PA fibrinolysis: The GUSTO-III experience. *J Am Coll Cardiol* 2001;37(suppl A):351A.
7. Langer A, Cannon CP, Goodman SG, Charlesworth A, Hill C, McCabe C, Braunwald E. International differences in acute coronary syndrome outcomes are related to angiography rates. *J Am Coll Cardiol* 2000;35(suppl.A):375A.
8. Langer A, Goodman SG, Reilly TM, Mousa SA, Racanelli AL, O'Connor C, O'Neill WW, Kleiman NS, Gurbel P, Daly RN. Second generation oral IIb/IIIa receptor blockade: phase II experience with roxifiban. *J Am Coll Cardiol* 2000;35(suppl.A):308A.
9. Ho Ping Kong W, Barr A, Goodman S, Langer A. Culprit vessel remodeling and reocclusion post-MI: CARS angiographic substudy. *Circulation* 1998;98(suppl.I):I-146.
10. Stewart DJ, Langer A, Goodman S, Barr A, Davies RF, Dupuis R, Ferguson J, Gardner MJ, Savard P, Sussex BA, Talajic M. Are calcium channel blockers post myocardial infarction safe? The CAMI experience. *Circulation* 1997;96(suppl.):I-700.
11. Langer A, Califf RM, Goodman SG, Fisher MR, Fuster V. Does higher intervention rate post MI result in better outcome in US vs Canada? *Circulation* 1996;94(suppl.):I-28.
12. Freeman MR, Goodman SG, Hsia T, Sloninko J, Mironov D, Hill C, Langer A. Prediction of extent of coronary artery disease early post infarction. *Circulation* 1996;94(suppl.):I-240.
13. Freeman MR, Goodman SG, Hsia T, Sloninko J, Mironov D, Hill C, Langer A. Prediction of extent of coronary artery disease early post infarction. *Can J Cardiol* 1996;12(suppl.E):116E.
14. Goodman SG, Langer A, Durica S, Raskob G, Comp PC, Gray RJ, Hall JH, Kelley RP, Hua TA, Lee RJ, Fuster V, for the Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Safety and anticoagulation effect of a low-dose combination of coumadin and aspirin. *Can J Cardiol* 1994;10(suppl. C):109C.
15. Singh N, Mironov D, Goodman SG, Morgan CD, Langer A. Treatment of silent ischemia in unstable angina: a randomized comparison of Isoptin SR versus Metoprolol. *Can J Cardiol* 1994;10(suppl. C):130C.
16. Goodman SG, Langer A, Topol EJ, Charlesworth A, Skene AM, Wilcox RG, Armstrong PW, for the LATE Study Investigators. Late thrombolysis improves prognosis in patients with ST depression. *Can J Cardiol* 1994;10(suppl. C):108C.
17. Goodman SG, Langer A, Topol EJ, Charlesworth A, Skene AM, Wilcox RG, Armstrong PW, for the LATE Study Investigators. Does late thrombolysis improve prognosis in patients with ST depression? *J Am Coll Cardiol* 1994; 23(suppl.):147A.

Miscellaneous Studies

ABSTRACTS - CONTINUED

18. Langer A, Goodman SG, Comp PC, Raskob G, Durica S, Gray RJ, Kelley RP, Hua TA, Lee RJ, Fuster V, for the Coumadin Aspirin Reinfarction (CARS) Pilot Study Group. Safety and anticoagulation effect of a low-dose combination of coumadin and aspirin. *Circulation* 1993; 88(suppl.):I-493.



Lined writing area consisting of 28 horizontal grey lines.



For more information, please contact us:

259 Yorkland Road, Suite 200 • North York, Ontario M2J 0B5
Tel: 416.977.8010 • 1.800.725.6585 • Fax: 416.977.8020 • 1.800.235.5335
Email: clinicaltrials@chrc.net • Website: www.chrc.net